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ABSTRACT
Simple, Label-Free and Non-Instrumented Analyte Quantitation by Flow Distance
Measurement in Microfluidic Devices

Debolina Chatterjee
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
Rapid determination of the concentrations of molecules related to diseases can provide timely
information for treatment options. However, most biomarker quantitation methods require costly
and complex equipment. On the other hand, point-of-care systems have less complex
instrumentation needs than laboratory-based equipment, but often provide less information; for
example, biomarker presence or absence instead of concentration. A complete analysis setup
addressing key limitations of both laboratory-based and portable systems is highly desirable.
I developed microfluidic devices with visual inspection readout of a target’s concentration from
microliter volumes of solution flowed into a microchannel. Microchannels are formed within
polydimethylsiloxane (PDMS), and the surfaces are coated with receptors. Capillary flow of
target solution in the channel crosslinks the top and bottom surfaces, which constricts the
channel and stops flow. The flow distance of the target solution in the channel before flow stops
indicates the target’s concentration, enabling simple visual inspection readout without complex
detection instrumentation. Because of its easy readout and portability, my system has great
potential for use in point-of-care diagnostics.
I initially demonstrated a proof-of-concept assay using biotin-streptavidin. Solution capillary
flow distances scaled linearly with the negative logarithm of streptavidin concentration over a
100,000-fold range. I measured streptavidin concentrations as low as 1 ng/mL using these
microsystems, demonstrating low detection limits. I also characterized the mechanism wherein
time-dependent channel constriction in the first few millimeters leads to concentration-dependent
flow distances.
I demonstrated the visual detection and quantification capability of my system to determine an
antigen target, thymidine kinase 1 (TK1). I developed surface modification methods for carrying
out flow assays and verified receptor attachment on channel surfaces using fluorescence imaging.
I obtained a 1 ng/mL TK1 detection limit in flow assays.
I also demonstrated nucleic acid quantitation in my flow devices. I detected specific DNA targets
in buffer and synthetic urine at 10 pg/mL levels. A dynamic range of 106 was obtained with

single-base mismatch specificity. DNA analogues of two miRNA biomarkers were measured
near clinically significant levels, showing great promise for future medical application.
The promising results demonstrate that this diagnostic tool offers a simple route to analyte
quantitation in microliter volumes, with excellent potential for point-of-care application.

Keywords: Analysis system, biomarkers, detectorless, microfluidics, point-of-care, quantitation.
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1. INTRODUCTION
1.1 ANALYSIS SYSTEMS
1.1.1 Advanced Analysis Systems
Analysis systems have continued to progress from glassware-based methods of classical
analytical chemistry to modern systems that are automated. An example of an automated,
modern system is high performance liquid chromatography (HPLC) which can separate, purify
and analyze samples.1 Gas chromatography coupled to mass spectrometry (GC-MS), another
widely known automated system, has been used for metabolic profiling of urinary samples and
organic pollutants in natural water and wastewater.2-3 Nuclear magnetic resonance spectroscopy
can detect hydrogen bonding in RNA structures4 or differentiate between tumor and non-tumoral
conditions,5 etc. Enzyme linked immunosorbent assay (ELISA),6 another advanced analysis
system used for clinical diagnosis, has been employed for quantification of various target
molecules. These analysis systems have excellent performance characteristics such as accuracy,
reliability, selectivity for target analytes, quantitation and low detection limits, but they lack
some desirable performance characteristics such as low cost, simplicity and portability.

1.1.2 Simplified Analysis Systems
Simplified analysis systems can be portable, which offers the convenience of easy use and low
cost. Point-of-care diagnostic devices7 such as glucometers to test for diabetes and pregnancy
kits are convenient options for diagnostic tests at the site of patient care without having to visit
clinics or hospitals. Paper-based microfluidic devices8 are easy-to-use, disposable and
equipment-free. Lateral flow immunoassays are also simple to perform and can detect the
1

presence (or absence) of a target analyte in a sample matrix.9 Sports drug testing approaches
utilize thin layer chromatography10 to reveal the presence of prohibited substances in a simple
manner. These simple and convenient analysis systems have several drawbacks such as poor
detection limits, no multiplexing, limited quantitation capabilities and marginal accuracy. A
detailed discussion of microfluidics, another type of simplified system, is taken up in the
following section (Section 1.2).

1.2 MICROFLUIDIC SYSTEMS
1.2.1 Introduction
Microfluidics deals with the manipulation of small volumes of liquid, at sub-milliliter scale, in
engineered micro-conduits in which the fluid can be maneuvered at will.11 The technology has
gained popularity in diagnostics and biological research due to its characteristic features such as
rapid sample processing and precise control of fluid in microchannels.11 One example of
microfluidics includes lab on chip or micro total analysis systems,12 that can combine various
processing steps, such as sample pretreatment, labeling, extraction, purification, separation and
detection, all on a single device, which forms a highly integrated system. This makes the
analyses quick and easy in an automated format. Droplet-based microfluidics is a type of micro
total analysis system where localized reactions take place in droplets separated by immiscible
fluid running through microchannels.13-14 This field has gained popularity and has extensive work
going on in single-cell studies,15 drug-protein binding,16 etc. Point-of-care (POC) diagnostics is
another widely developing field of research that can utilize a microfluidic platform to encourage
preliminary self-screening and disease testing at home, as well as quicker diagnosis without
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requiring expert clinicians in military applications and forensics.7,17 Another application is cell
analysis in microfluidics which has led to numerous developments in cell biology18-19 and singlecell analysis.20 Microfluidic approaches have also been used with great success for nucleic acid
assays such as in DNA hybridization21-22 and nucleic acid amplification.23. The microscale
dimensions of the microfluidic platform have also been used to generate physiological redundant
conditions that simulate the inside of the human body to study in vitro drug metabolism.24 The
physiological-like conditions thus generated can be well regulated in microfluidic channels for
better control.25 Microfluidics also offers enabling capabilities in the field of proteomic analysis
for identification of proteins and their quantitation.26-27 Research in environmental analysis using
microfluidic devices is also being performed.28 An aerosol analyzer with parts connected to a
microchip has performed online monitoring of aerosol composition with comparable results to a
full-size instrument.29 Microfluidics offers many advantages when compared to benchtop
analyzers such as small sample volume consumption, shorter diffusion times and portability that
can be utilized on-site.30

1.2.2 Materials
Materials for microfluidics can be categorized into several subtypes; namely, inorganic, which
includes glass and silicon, and polymeric, which can be further categorized into elastomeric,
thermoplastic, and paper, which is an emerging alternative.

Inorganic materials, i.e., silicon and glass, have been widely used for micromachining. Silicon
has a surface chemistry based on the silanol (-SiOH) group; thus, surface modification via
silanes is easily accomplished. Silicon is transparent to infrared, but not UV or visible light, thus
3

making UV or visible imaging challenging for structures embedded in silicon. Transparent
materials such as glass (or polymers) can overcome this issue. Glass has low background
fluorescence and, as with silicon, has surface chemistry based on silanols. In addition, glass is
compatible with biological samples and has relatively low non-specific adsorption of
biomolecules, but is not gas permeable, which makes it problematic for studying cells or other
molecules that require oxygen permeability through microchannels.

Inorganic materials have been overshadowed by polymeric materials in part because the latter
are economical, easy to fabricate and have an immense variety of types to choose from.31
Polymers are organic-based materials with long chains having physical and chemical properties
related to the functional groups present. Hence, these polymeric materials are chosen according
to the applications intended by the consumer.

Poly(dimethylsiloxane) (PDMS) is an elastomeric polymer that has many applications in
biomedical engineering due to its advantages such as ease of fabrication and replica molding,
where several layers can be prototyped for complex design formations. In addition, its high
flexibility with low elastic modulus (300-500 kPa) makes PDMS suitable for pump and valve
fabrication. Moreover, PDMS is oxygen permeable and can be used for cell studies inside
microchannels. Finally, PDMS’s optical clarity makes its coupling with UV or visible detectors
feasible.32 PDMS is however prone to non-specific fouling because it is a hydrophobic
polymer.33

4

Thermoplastic substrates for microfluidics are polymers that retain their shapes under normal
temperatures, but are moldable when heated to their glass transition temperatures.32 An example
of such is poly(methyl methacrylate) (PMMA). It has a 3.3 GPa elastic modulus,34 which is
much higher than that of PDMS, so it is poorly suited for use in valving or pumping. However,
PMMA has good optical clarity, is biocompatible and is less prone to surface fouling than PDMS.
Hence, PMMA microdevices have been used for the quantification of several biological
molecules related to diseases. Yang et al.35 quantified alpha-fetoprotein, a cancer biomarker,
using an integrated PMMA microdevice with fluorescence detection. A different material,
polymerized poly(ethylene glycol) diacrylate (poly-PEGDA),36 is an alternative to PDMS since
poly-PEGDA is resistant to non-specific surface fouling due to hydrophilic poly(ethylene glycol)
(PEG) functional groups. Electrophoretic separations in poly-PEGDA microdevices have shown
good resolution and symmetrical peaks.36 However, poly-PEGDA has an elastic modulus of ~0.1
GPa,37 much higher than PDMS but lower than PMMA; thus, it cannot be used for fabricating
self-collapsing valves, but it has enough flexibility for use in membrane-pedestal valve designs.38
My focus will be on polymers for the rest of this dissertation since my research involves flexible
polymer microdevices with potential biological applications.

1.2.3 Polymer Device Fabrication Techniques
The fabrication of polymeric microdevices consists of pattern transfer and bonding, which differs
for different polymers depending on their material properties. Soft lithography is usually
employed for pattern transfer in elastomers such as PDMS, while hot embossing, injection
molding or laser ablation are commonly used for thermoplastics. Surface activation by plasma
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oxidation is the most common method for bonding in elastomers, while thermoplastics rely on
solvent or thermal bonding for the final step to form a complete device.

Soft lithography is experimentally convenient and useful for various applications such as
adherent and non-adherent single cell studies,39 lab-on-chip (particle and droplet manipulation
using surface acoustic waves),40 flexible electronics, etc. In soft lithography, a prepolymer
mixture is poured on a master mold with features (created by photolithography) and cured. The
patterned replica is then peeled off the master mold and usually plasma bonded to another piece
of unpatterned polymer, glass or silicon to form the complete device.41 PDMS microchannels can
undergo surface modification using gas-phase methods, wet chemical processes or a combination
of gas-phase and wet chemical methods.42 Gas-phase methods include plasma oxidation, where
Si-CH3 groups in PDMS are converted to Si-OH, thus rendering the surface hydrophilic.42 Other
gas-phase methods are ultra-violet irradiation, chemical vapor deposition and sputter coating of
metals.42 Wet chemical methods include layer-by-layer deposition, sol-gel coatings, silanization,
dynamic coating with surfactants and protein adsorption.42 A combination of gas-phase and wet
chemical methods involves silanization on plasma-oxidized PDMS.42 A more detailed discussion
of silanization of plasma-oxidized PDMS is given in Section 3.1.1.4, where I describe a process
used in my research work.

Pattern transfer in thermoplastics usually entails hot embossing, injection molding or laser
ablation. Hot embossing involves pressing a master template with features onto a polymer piece
for a particular period of time at a temperature above the glass transition temperature of the
polymer. This transfers the design of the template into the polymer material.43 In injection
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molding, molten polymer under high pressure and temperature conditions is introduced into a
cavity containing a patterned mold where the polymer is shaped. The shaped replica is then
removed after cooling the mold.44 This process is widely used to create many things including
bottle caps, automotive dashboards, wire spools, packaging, some musical instruments, storage
containers, mechanical parts such as gears, etc.,45 and hence is desirable due to its scalability and
continuous manufacturing capability. In laser ablation, a high power laser creates patterns on the
thermoplastic polymer by removal of material. It is a highly tunable process with respect to the
variety of features that can be formed. However, not all kinds of thermoplastic polymers can
withstand the laser power owing to changes in surface chemistry during this process.46
Additionally, incomplete material removal by the laser can require additional cleaning steps, thus
making the process more cumbersome.

Thermoplastic materials can be bonded thermally or by solvents or adhesives. Thermal bonding
occurs by pressing the patterned and unpatterned substrates together in an oven or hot press at a
temperature which leads to mixing of the polymer chains together at the contact points between
the two surfaces, leading to bonding.47 This method is simple and the bond strength is good, but
it can produce deformed microchannels.48 Solvent bonding occurs upon exposure of the substrate
surfaces to solvents (usually organic) which soften the exposed polymer surfaces and, when put
together, facilitate their sticking together. However, the softened polymer sometimes fills in the
channels as well. This issue is overcome by using sacrificial layers for protection such as
paraffin wax49 or water.50 Adhesive bonding is similar to solvent bonding but uses glues, epoxies,
etc., to bond the substrate pieces.47 Sometimes this leads to clogging of the channels due to
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adhesive flow through them, which is a drawback.51 However, adhesive bonding has advantages
such as low bonding temperatures and good bonding strength.

1.2.4 Types of Flow
1.2.4.1 Pressure-driven flow
Pressure-driven flow is generated when there is a difference in the pressure along the
longitudinal direction in the microchannel. The pressure difference can be generated by external
pumping such as in case of syringe pumps attached to a microdevice,52 or by peristaltic pumping
or acoustic pumping. The flow profile is parabolic in case of pressure-driven flow,53 meaning
that the fluid stream has a maximum velocity in the center and minimum at the edge of the
channel.

Flow rates delivered by syringe pumps are considered to be highly precise,52 but externally
attached parts for pumping increase the dead volume from interfacing with pumps. In acoustic
pumping, the interaction of longitudinal waves with the surrounding fluid is used for moving the
liquid.54 There are no byproducts generated in this type of pumping, but denaturation of
biomolecules is sometimes observed. Pneumatic peristaltic pumps are mechanical pumps which
function by sequential actuation of a series of pneumatic microvalves with pressure. These can
be easily integrated and have fast response times, but have pulsed fluid flow and require an
external source to provide pressure. .55
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1.2.4.2 Capillary flow
Capillary flow is the spontaneous fluid motion through a capillary by a combination of cohesive
forces within a liquid (surface tension) and adhesive forces between the liquid and the channel
wall, which act to move the liquid. Capillary flow does not require any external parts for driving
the fluid flow, but there is less control over fluid flow;32 thus, processes such as mixing are
difficult to produce.Capillary flow-driven microfluidic biosensors can help to meet the needs of
point-of-care diagnosis in resource-limited areas since no parts are required for driving samples
through the biosensor.56 The velocity of capillary flow of fluid through a straight channel is given
by equation 1.1,57
u = (å r2 Pc)/(8 µ x)

(1.1)

where u is the capillary flow velocity, å is a constant associated with the channel cross-section
and shape, r is the radius (r is replaced by h for rectangular cross sections), Pc is the capillary
pressure across the interface (air-water interface for example), µ is the fluid viscosity and x is the
location of the interface measured from the inlet. Equation 1.2 gives an expression for Pc in a
rectangular channel, 57
Pc = σ [(cosϴ1 + cosϴ2)/w + (cosϴ3 + cosϴ4)/h]

(1.2)

where, σ is the surface tension, ϴ1 and ϴ2 are contact angles for left and right side walls, while
ϴ3 and ϴ4 are contact angles for top and bottom walls. Equation 1.2 simplifies in case of a
circular cross-section to equation 1.3.57
Pc = 2 σ cosϴ / r

(1.3)

Hence, from equations 1.1 and 1.3, the capillary flow velocity in a circular cross-section channel
is given by equation 1.4.
u = (å r σ cosϴ)/(4 µ x)

(1.4)

9

Thus, capillary flow is affected by channel surface wetting, surface tension, shape and material,
and is inversely proportional to the fluid viscosity.

1.2.4.3 Electrokinetic flow
Electrokinetically driven flow consists of electroosmotic, electrophoretic, electrochemical and
magnetohydrodynamic modes. Solution in contact with a charged surface leads to formation of
an electrical double layer (an inner rigid or Stern Layer and an outer diffuse layer) due to
attraction of oppositely charged ions to the surface charges (see Figure 1.1).58 An electrical
potential (Zeta potential) is created, with the potential decreasing with increasing distance from
the surface.58 When an electric field is applied, one type of occurring flow is electrophoretic,
which drives charged ions toward the oppositely charged electrode; this flow is dependent on the
charge and size of the ion and viscosity of the solution. Another type of flow that occurs is
electroosmotic flow (EOF), where cations within the loosely bound diffuse layer move toward
the cathode and drag the bulk solution along (Figure 1.1). The overall electrokinetic flow is a
combination of electroosmotic and electrophoretic flow and can be used to separate cations and
anions in a solution in a method called capillary electrophoresis.32 Electroosmotic pumps are
non-mechanical and can be easily integrated into microfluidic devices with additional advantages
of flow rates that can be manipulated. However, EOF pumps only work with conductive
solutions.

10

Figure 1.1. EOF in a negatively charged channel.

Two other electrokinetically driven flow methods are described here. Electrochemically driven
pumps are low power pumps which depend on gas bubbles generated by electrolysis to drive
fluids.59 Magnetohydrodynamic pumping involves the Lorentz force produced by the interaction
of orthogonal electric and magnetic fields with a conducting fluid in a microchannel.60 These
non-mechanical pumps can be easily integrated into microfluidic devices with additional
advantages such as small size in the case of electrochemical pumps, and continuous flow in the
case of magnetohydrodynamic pumps. Some disadvantages include blockage issues by
byproducts generated in electrochemical pumps and bubble formation in the case of
magnetohydrodynamic pumps. Electrokinetic flow has been used in microfluidic systems for
various lab-on-chip applications from biomolecule separations to enrichment and purification.32

11

1.3 QUANTIFICATION OF HEALTH-RELATED ANALYTES
One of the greatest challenges of science and engineering is to improve the health of people by
development of technology for the poorest regions of the world. Quantification of health-related
analytes thus plays a major role in that regard.
1.3.1 Biomarkers
Biomarker diagnostics are the analysis of target compounds with the final goal of detecting a
disease or its causative agent.61-62 These biomarkers, measured in body fluids or tissue, can
indicate the disease state, its progression characteristics and its response to therapies.63 Thus,
biomarkers can verify the existence of and give information about a disease.
1.3.1.1 Proteins
One important class of biomarkers includes proteins, which when present at elevated or
depressed concentrations in serum, plasma, tissue or saliva can be indicative of disease states.
Thus, accurate, sensitive and multiplexed detection of protein biomarkers holds significant
promise for early disease diagnosis and therapy guidance. Some important cancer protein
biomarkers include prostate specific antigen (PSA), interleukin 6 (IL-6), carcinoembryonic
antigen, cancer antigens (e.g., CA-125), c-reactive protein and α-feto-protein (AFP).64

PSA is found at elevated levels in prostate cancer (PC) patients.64 However, screening for PC
suffers from the limited specificity of PSA testing. Also, elevated serum levels of PSA have been
found in non-malignant conditions, leading to unnecessary biopsies. Finally, the PSA level
reflects a spectrum of PC risks with the possibility that a proportion of PCs might be missed
when the PSA threshold for screening is followed.65 IL-6 is a cytokine associated with several
different types of cancer, one of which is head and neck squamous cell carcinoma (HNSCC). In
12

healthy individuals, the mean serum IL-6 levels are less than 6 pg/mL, whereas in HNSCC
patients the levels are more than 20 pg/mL.64 AFP is a glycoprotein associated with liver cancer.
Its normal levels in healthy adults are less than 400 ng/mL, but concentrations rise above 400
ng/mL in patients with hepatocellular carcinoma.66 The clinically relevant levels of most
biomarkers in diseased states lie in the ng-pg/mL range, which calls for highly sensitive and
specific analysis systems for quantification of biomarkers and disease diagnosis.67

1.3.1.2. Lipids
Lipidomics is the study of lipid biomarkers or lipid metabolites to better understand diseases.
Lipidomics has been considered important for the study of mechanisms and biomarkers for many
diseases such as atherosclerosis, hypertention, diabetes and cancers.68 For example, cholesterol in
the form of total blood cholesterol and/or high density lipoprotein is used as a lipid biomarker for
risk assessment of heart disease; triglyceride concentration is used for risk assessment of heart
disease and diabetes; while phosphatidylethanolamine, ether-linked phosphatidylethanolamine,
and ether-linked phosphatidylcholine lipid classes have been considered to be biomarkers in
diagnosis of prostate cancer.68 In cancer, lipogenesis has been seen to increase due to
overexpression of several lipogenic enzymes such as ATP citrate lyase, acetyl Co-A carboxylase
or fatty acid synthase. They increase cancer growth by formation of excess lipid containing
molecules involved in cell signaling.69 For example, one lipid messenger that promotes cancer
development is phosphatidylinositol-3,4,5-triphosphate, which activates protein kinase B/Akt to
promote cell proliferation and survival;70 another is lysophosphatidic acid, which promotes
cancer aggressiveness by signaling through G protein-coupled receptors;71 and a final example is
prostaglandins, which support migration and tumor-host interactions.72
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1.3.1.3. Nucleic Acids
Mutated forms of DNA in diseased patients as compared to healthy individuals (genetic studies)
can act as disease biomarkers. Concentrations of circulating nucleic acids (mRNA, miRNA, etc.)
can also act as biomarkers. DNA sequencing is the method for precisely determining the order of
nucleotides in a strand of DNA or a DNA molecule. Massively parallel DNA sequencing
technologies have increased the ability to generate large amounts of sequencing data at a rapid
pace and have become indispensable for basic biological research and for applied fields such as
disease diagnostics.73 DNA sequencing usually requires an amplification step to enable the
sequenced signal to be measured by an optical system, which isusually fluorescence-based.73
DNA sequencing has been used to determine single nucleotide polymorphisms (SNPs), which
are DNA sequence variations in a single nucleotide. SNPs have been associated with several
diseases. For example, a single-base mutation in the apolipoprotein E gene is associated with a
high risk of Alzheimer disease.74 Other examples of diseases linked to SNPs are bipolar disorder,
breast cancer, coronary artery disease, Crohn’s disease, prostate cancer, schizophrenia, systemic
lupus, diabetes, etc.75

MicroRNAs (miRNAs) are 19-24 base long noncoding RNA oligonucleotides, which block
translation of mRNA, and, hence, play critical roles in cell function.76 Circulating miRNAs are
found in serum, plasma, urine, saliva and other body fluids and are resistant to RNase activity, as
well as able to withstand extreme temperature (freeze-thaw cycles) and pH (1-13 pH)
conditions.77 These features, in addition to differential levels of miRNAs in diseased states, make
them useful biomarkers in diagnosing and monitoring various diseases including cancer, diabetes,
14

tissue injury, etc. For example, some miRNAs have been found to be up-regulated or downregulated in cancer and, thus, have promise to serve as biomarkers for cancer classification.76
Mir-141 was found at elevated levels in plasma of prostate cancer patients, while mir-25 and
mir-223 have been found at increased levels in lung cancer patients’ serum compared to normal
serum. Differential expression of mir-126 and mir-182 in urine identified bladder cancer,78 while
mir-125a and mir-200a were present at lower levels in saliva of oral squamous cell carcinoma
patients than in control subjects.79

1.3.2 Analysis Methods
Quantifying biomarkers is crucial for early detection of disease, so treatment can be administered
quickly to patients. Two techniques used for detecting and quantifying protein biomarkers are
enzyme-linked immunosorbent assay80 and western blotting.81 Various other methods for protein,
lipid, metabolite and nucleic acid biomarker identification include liquid chromatography
coupled to mass spectrometry,82-83 Raman spectroscopy,84 capillary electrophoresis coupled to
mass spectrometry,83 etc. All of these techniques take hours to complete an assay,80, 85, 86 which
hinders immediate diagnosis. In addition, the above techniques require complex instrumentation,
can be expensive to perform and generally lack the convenience of portability.

Numerous methods have been developed to detect SNPs, for example allele-specific biochemical
enzymatic reactions,87 selective ligation with an optical indicator such as a fluorescent dye,88-89
electrophoresis with additives90 and nanopores containing molecular probes.91 Most of the
methods rely on enzymatic, chemical, optical or electrical signals for detection, which can be
cumbersome. Nanopore membranes provide a simple and fast platform since detection is
15

achieved by DNA hybridization with molecular probes immobilized on nanopore walls.
However, the disadvantages to this process include the difficulty and poor reproducibility of
nanopore preparation and specific surface functionalization of the nanopore wall.92 Block
copolymers have been used for nanochannel fabrication followed by immobilization of DNAbased molecular recognition agents for SNP detection.93 The use of block copolymers provided
uniformity in nanostructures formed, and SNP detection was highly precise and efficient.
However, long reaction times and rigorous conditions with block copolymers during fabrication,
in addition to the use of dyes for detection made the fabrication and analyses processes complex.

Some methods have been developed for miRNA measurement. Quantitative reverse transcription
PCR, which is the gold standard for sequence-specific RNA quantitation, does not work for
miRNAs since they are about the same length as standard PCR primers.94 An amplification-based
enzymatic bioluminescence miRNA assay95 provides 10 pg/mL detection limits, but the use of
enzymes and their costs are disadvantages. In-situ hybridization with locked nucleic acid
probes96 can determine native locations of miRNAs inside cells and tissues, but requires a
fluorescence microscope, and suffers from low throughput and high background signal.
Microarray hybridization-based methods97 for miRNA profiling offer high throughput but require
a labeling step for detection, thus increasing complexity and cost. Label-free miRNA detection
methods involving nanopores98 and surface plasmon resonance99 have also been developed, with
detection limits in the mid-fM range. Although sample preparation is simplified because labeling
is not needed, sophisticated instruments and/or complex data interpretation are required, thus
hindering their use in simple, point-of-care diagnostic settings.
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1.3.3 Need for simple, quantitative, health-related assays
Some challenges from instrumentation requirements can be overcome by point-of-care
diagnostics.100 Point-of-care diagnostics bring the diagnosis, conveniently and immediately, to
the patient, allowing the patient to receive therapeutic relief more quickly. Thus, diagnostic
testing can be performed near the patient without needing a clinical lab, which can lead to rapid
testing followed by intervention. The point-of-care diagnostic system must be portable, fast and
cost effective so it can be carried in the field or taken to homebound people or individuals in
resource-limited areas. For example, this could help in controlling infectious diseases such as
tuberculosis, malaria, cholera, etc. in Third World countries. Point-of-care diagnostics have been
applied to various tests, such as for pregnancy,101 drugs102 and some infectious diseases including
streptococcal sore throat103 and HIV-AIDS,104 but a key limitation of many of these diagnostics
is quantitation. Point-of-care tests usually provide qualitative results (i.e., “presence” or “absence”
of the causative agent is indicated), but information on the amount present, which can indicate
the stage or severity of the disease and inform treatment, is not obtained. Thus, there is a great
need for simple, quantitative, health-related assays which address the key limitations of
laboratory-based equipment as well as portable point-of-care systems.

1.4 OVERVIEW OF DISSERTATION
I have developed a novel quantitative analysis method that can be field operated and can quantify
disease relevant biomarkers without the aid of complex instrumentation. This method has the
potential to serve as a point-of-care diagnostic device. In this chapter, I introduced analysis
systems, including microfluidic ones, and gave a brief overview of materials, fabrication
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techniques and types of fluid flow involved in microfluidic systems. In addition, I discussed
various biomarkers relevant to diseases and the means of analyzing them.

In Chapter 2, my novel assay method, which involves flow distance measurement as a means to
measure target concentration visually, is introduced. I describe the fabrication process of PDMS
microfluidic devices and the necessary surface modification methods required for target-receptor
interaction to constrict the microchannels. Flow assays were performed using biotin-streptavidin
as a model system. I obtained optimized conditions for performing chemical measurement of the
target molecule by characterizing different factors influencing the flow distance. Also, a
plausible mechanism involved in the correlation between target concentration and flow distance
travelled was identified and evaluated.

In Chapter 3, various surface attachment methods were evaluated for carrying out flow assays
using antigen-antibody interaction. Initial working conditions for attachment of an antibody to
thymidine kinase 1 (TK1, a cancer biomarker) to microfluidic channels were obtained. The
uniformity of the attachment was also verified by fluorescence imaging of the fluidic channels.
In addition, a flow assay to determine TK1 concentrations by flow distance measurement in antiTK1-modified channels was performed and the results were discussed.

In Chapter 4, target quantitation by flow distance measurement was extended to nucleic acid
analysis. DNA analogues of miRNAs were used as targets whose flow distances in
oligonucleotide-modified microfluidic channels were correlated with concentrations. Also,
mismatched sequences were used as targets to evaluate the sensitivity of the system to detect
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single-base mismatches; flow distances were different from those of the perfect complement.
DNA analogues of miRNAs in urine samples were measured at 10 pg/mL levels, which are near
the actual concentrations of miRNAs in urine. Additional experiments were performed, which
indicate that flow time, in addition to flow distance can be correlated with target concentration in
my devices.

Conclusions reached from my research work are discussed in Chapter 5. Suggested future work
is highlighted including etched scales on microdevices, designs for direct loading of samples,
dual-height channel designs, multiplexing using complex device designs and working with an
aptamer-based system for analyzing small molecules.
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2. “FLOW VALVE” MICROFLUIDIC DEVICES FOR SIMPLE, NONINSTRUMENTED, AND LABEL-FREE ANALYTE QUANTITATION *
2.1 INTRODUCTION
Advanced analysis systems have a number of important desired performance characteristics,
namely accuracy, reliability, selectivity for target analytes, quantitation, low detection limits,
simplicity, speed, cost, multiplexing, and so on. Frequently, there is a tradeoff between these
objectives (e.g., low cost vs. high accuracy), requiring a compromise that best meets the analysis
requirements. For example, the performance of benchtop analyzers takes precedence over
portability, while for point-of-care (POC) systems, versatility and performance are often
sacrificed in favor of convenience.

A number of automated and robust laboratory-based systems are available for analyses. Liquid
chromatography1 is widely used and has seen recent progress in stationary phases2, 3 and with
increased pressures.4 Mass spectrometry methods5,

6

have advanced through improved mass

analyzers7 and sample introduction techniques.8 Spectroscopy can provide analyte-specific
information from absorbance9 or Raman10 techniques. In addition, clinical diagnostic tools11 such
as enzyme-linked immunosorbent assay (ELISA)12 are broadly used for targeted detection of

Reprinted with permission from Chatterjee, D.; Mansfield, D. S.; Anderson, N. G.; Subedi, S.; Woolley,
A. T. Anal. Chem. 2012, 84, 7057-7063.
*
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biomolecules of interest. The above examples nicely illustrate systems with excellent
performance, but with capability that generally comes at the expense of portability.

On the other hand, portable instruments offer significantly increased analysis convenience. For
example, POC diagnostic devices have been implemented in monitoring blood glucose for
diabetes13 and in home pregnancy testing.14 Paper-based microfluidic systems15-17 offer
simplified analysis coupled with low cost. These portable systems are advantageous in terms of
simplicity and speed, but this generally comes at the cost of some performance characteristics
such as low detection limits, quantitation capabilities or multiplexing. In this chapter, I describe a
simple, portable and detectorless microdevice system with quantitation capabilities at ~1 ng/mL
detection limits and potential for broad applicability, addressing key limitations of both benchtop
and portable systems.

My method involves capillary flow of target solution through a receptor-coated microchannel in
a deformable material, which leads to channel constriction and flow stoppage due to targetreceptor interaction. Importantly, in this “flow-valve” method, the distance of capillary flow is
correlated with the target’s concentration, and the ability to differentiate between filled and
empty channels visually enables detectorless determination of flow distance and, hence, target
concentration. The use of flow distance as a quantitative detector is somewhat complementary to
work of Zhong et al.,18 who demonstrated a microfluidic adsorption-length-based approach for
quantifying peptides, albeit requiring external mass spectrometry detection. I have fabricated
polydimethylsiloxane (PDMS) devices and tested them with the model target-receptor system of
streptavidin and biotin. Furthermore, I have studied three factors that affect assay performance:
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solution viscosity, device material thickness and channel height. I have also measured the
concentration dependence of flow distance and assayed streptavidin solutions as dilute as 1
ng/mL. Finally, I have evaluated the mechanism of channel closure in these assays. Notably, the
“flow valve” approach should be adaptable to various target-receptor pairs, offering a very
broadly applicable analysis method.

2.2 EXPERIMENTAL SECTION
2.2.1 Mold design and preparation
Molds were prepared using a 500 µm thickness, 10 cm diameter glass wafer (Fig. 2.1A) with
spun on AZ50XT positive photoresist (AZ Electronic Materials, Branchburg, NJ) of 5-20 µm
thickness (Fig. 2.1B). Next, photolithography was used to transfer the serpentine design of the
mask (Fig. 2.2A) onto the glass wafer by UV exposure followed by development in AZ400K
developer (AZ Electronic Materials), resulting in elevated features of 50 µm width on the wafer
(Fig. 2.1C). Reflowing of photoresist19 was then done at 150 ºC for 5 min to round the edges of
the elevated features in the mold (Fig. 2.1D).

2.2.2 PDMS device fabrication
Devices were fabricated by casting PDMS against the positive relief mold. PDMS (Dow Corning,
Centennial, CO) was prepared by mixing the base and curing agent in a 10:1 ratio, pouring it on
the mold to a thickness of 0.45-1.1 mm (Fig. 2.1E), and heating to 80 ºC for 45 min for curing.
This PDMS was removed from the mold (Fig. 2.1F) and bonded to an unpatterned PDMS layer
(thickness: 0.4-1.1 mm) after exposure to an oxygen plasma for 30 s20 to form a completed
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device with embedded channel (Fig. 2.1G). Loss of fabrication reliability prevented the usage of
devices with PDMS films thinner than ~0.4 mm. After plasma bonding, devices were stored with
water in the channels to ensure that the surface remained hydrophilic.

Figure 2.1. “Flow valve” device fabrication and channel closure process. Microchannel and PDMS layer
dimensions are not shown to scale. (A) Glass wafer (gray). (B) AZ50XT positive photoresist (black) spun on wafer.
(C) Photolithographic patterning to form a mold with elevated feature using UV exposure and development with
AZ400K developer. (D) Reflowing of photoresist at 150 ºC for 5 min to yield a curved feature. (E) PDMS cured (80
ºC, 45 min) on mold. (F) Cured PDMS released. (G) Plasma bonding to enclose the microchannel. (H) Cross section
zoom view of the open channel in (G) coated with receptors. (I) Zoom view (~1000X) of the boxes in (H), showing
receptors on the top and bottom channel walls. (J) Cross section of a partially closed channel. (K) Zoom view
(~1000X) of the box in (J), showing receptor-target interaction leading to channel closure.

28

Figure 2.2. Flow-valve assay concept and data, with device schematic (top) and photograph (bottom) in each panel.
Devices had biotinylated-BSA coated channels 17 µm tall and 58 µm wide, and a PDMS cover layer thickness of
0.5 mm. White arrows indicate direction of flow. (A) Open and empty channel, visible as no solution is in it. (B)
Channel filled with solution lacking streptavidin, which travels the entire length of the channel without stopping,
making the channel difficult to distinguish from the surrounding device. (C) 32 mm flow distance for 10 µg/mL
streptavidin solution loaded in the channel. (D) 83 mm flow distance for 100 ng/mL streptavidin solution added to
the channel.

2.2.3 Procedure for experimentation
Experiments were carried out on a biotin-streptavidin model system using the general protocols
given here. The water-filled microchannel was first aspirated and then filled with biotinylated
bovine serum albumin (b-BSA, Thermo Scientific, Rockford, IL, 2 mg/mL in 0.14 mM citrate,
pH 6.8) or a control solution of BSA (Sigma-Aldrich, St. Louis, MO, 2 mg/mL in phosphate
buffered saline, PBS) via capillary action. The b-BSA was allowed to adsorb to the PDMS
channel walls for 15 min, leaving exposed biotin groups. Then, the b-BSA solution was removed
and the channel was flushed with PBS (10 mM, pH 7.2) to remove unadsorbed material. Finally,
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PBS was aspirated from the channel and a 1 µL streptavidin solution (New England Biolabs,
Ipswich, MA) of specified concentration in PBS was pipetted into the reservoir (see Fig. 2.2C-D).
The flow distance of streptavidin solution in the microchannel was measured with a ruler, and
photographs were obtained with a digital camera. Some flow experiments were also carried out
with streptavidin solutions having added glycerol (0-36%) to explore the influence of viscosity.

2.2.4 Flow restriction mechanism
Fluorescein sodium salt (80 ng/mL, Spectrum, Gardena, CA) in PBS was mixed with unlabeled
streptavidin or BSA as a control (both 500 µg/mL in PBS) and allowed to flow in 13 µm tall
biotin-modified microchannels.

Fluorescence signal was monitored using a CCD camera (CoolSNAP HQ2, Photometrics,
Tucson, AZ) attached to an upright microscope (Axio Scope, A1, Zeiss, Thornwood, NY).
Illumination was provided by a 625 mW LED (MBLED, Thorlabs, Newton, NJ) that passed
through a filter cube (FITC-LP01-Clinical-OMF, Semrock, Rochester, NY). Images were
acquired using a 400 ms exposure time. Image acquisition and data analysis were performed
using Image J software. The fluorescence signal from fluorescein in these images, integrated
across the channel at different flow distances, was obtained. From these traces, background
subtracted and normalized channel fluorescence signal peak areas (proportional to channel crosssectional areas) were obtained for flow solutions containing either streptavidin or BSA (control).
Contact angles of streptavidin solution droplets of different concentrations on biotinylated
PDMS substrates were measured using a contact angle goniometer (Rame-Hart, Succasunna, NJ).
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2.3 RESULTS AND DISCUSSION
Experiments on a model system, biotin-streptavidin, were conducted to test the devices and
enable their optimization. I studied the effects on flow distance of channel height and shape,
PDMS cover layer thickness, and solution viscosity. I also probed the mechanism through which
channel closure affects flow. Figure 2.2 shows a few examples of the data resulting from “flow
valve” assays. Unfilled flow channels are easily seen in the photographs (e.g., Fig. 2.2A), and
similarly under simple visual inspection. In contrast, microchannels containing liquid, as
demonstrated in Figure 2.2B, are no longer seen readily.

Initial experiments were conducted on 35 mm long, 58 µm wide channels with a 1.1 mm thick
PDMS cover layer. Channels with a height <5 µm usually became blocked by the flow of only
water or during coating with b-BSA, either because of channel deformation due to capillary
forces or due to surface crosslinking during BSA adsorption. In a revised device design with
slightly taller microchannels (5.2 µm) and a PDMS cover layer thickness of 0.7 mm, a 1.0
mg/mL streptavidin solution traveled 10 mm, and a 0.88 mg/mL streptavidin solution traveled 15
mm, while solutions lacking streptavidin flowed the full length (35 mm) of the b-BSA coated
channel. When glycerol was added to a 28% concentration, a solution with a streptavidin
concentration of 60 µg/mL flowed 30 mm in a 5.2 µm tall channel with a 0.7 mm PDMS cover
layer thickness. These experiments identified three assay parameters (channel height, cover layer
thickness and solution viscosity) that could be altered to affect the dynamic range and limit of
detection for “flow valve” experiments. Reproducible results for these initial device designs were
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still somewhat difficult to obtain, which I attribute to the above-noted blockage issues associated
with relatively shallow channels.

A curved channel cross-section (Fig. 2.1G) was necessary for channel constriction, probably
because pinching shut from the sides towards the center was possible with this geometry (see Fig.
2.1H, J). A scanning electron micrograph of a channel cross-section is given in Figure 2.3
confirming the curved shape. I did flow experiments with curved and rectangular cross-section
channels coated with biotin (both 58 µm wide and 5.2 µm tall with a 0.7 mm PDMS top layer
thickness); 1.0 mg/mL streptavidin solution flowed only 10 mm in the curved cross-section
channel before flow stopped, but the same solution flowed the full length of the rectangular
cross-section channel. My results with this channel geometry are also consistent with published
work, showing that a curved channel is easier to close than a rectangular channel for valves
actuated by external pressure.21

Figure 2.3. Scanning electron micrograph of channel cross-section.
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Building on these initial studies, I further characterized the three factors that affected channel
closure: solution viscosity, PDMS cover layer thickness and channel height. I varied one
parameter while holding others constant and observed any effects on the flow distance. I also
used taller (13-17 µm) channels to avoid some of the issues previously seen with shallower ones.
When a higher streptavidin concentration (10 µg/mL) was introduced into a biotin-modified
channel (Fig. 2.2C), more rapid cross-linking of the biotin anchored to the surface in the first few
millimeters of the channel length led to faster constriction at the start of the channel and a shorter
capillary flow distance traveled by the streptavidin solution. On the other hand, when a lower
concentration of streptavidin solution (100 ng/mL) was loaded (Fig. 2.2D), slower cross-linking
led to a greater capillary flow distance for the streptavidin solution before constriction in the first
few millimeters of the channel stopped flow. A more in-depth discussion of this hypothesized
mechanism of channel closure and flow stoppage is provided later.

The effect of solution viscosity on the flow distance was studied with other variables held
constant. Added glycerol adjusted the solution viscosity, and control solutions containing
glycerol but lacking streptavidin flowed the entire length of the microchannels. Figure 2.3 shows
the effects of solution viscosity (1.0-3.2 cP, corresponding to glycerol concentrations of 036%)22 on flow distance for 100 ng/mL and 1.0 µg/mL streptavidin. There was little effect on the
flow distance for viscosities less than ~2 cP (24% glycerol), but with further increases in
viscosity, the flow distance decreased. Below 2 cP, the solution viscosity also had little effect on
flow velocity (10-12 s to flow 80 mm, with or without glycerol). However, above 2 cP, the
solution viscosity led to slower solution flow through the channel that increased the time for
biotin-streptavidin interaction and closure of the first few millimeters of the channel. Thus, the
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distance solution traveled before channel constriction restricted flow was shorter for both
concentrations of streptavidin. The 100 ng/mL solutions travelled a greater distance than the 1.0
µg/mL ones, in line with expectations. I further found that added glycerol could be used to adjust
the linear range for detection for a given microchannel length, although adding glycerol
increased the assay complexity compared to flowing solution without viscosity adjustment.
Indeed, flow experiments done in duplicate in glycerol-adjusted 3.0 cP solutions in biotinmodified 17 µm tall channels yielded the following results: control solutions lacking streptavidin
flowed 95 and 100 mm; solutions containing 1 ng/mL streptavidin flowed 56 mm and 67 mm;
and 100 pg/mL streptavidin solutions (a factor of 10 lower concentration than we have been able
to detect reliably in 1.0 cP solutions) flowed 71 mm and 84 mm. It is also valuable to understand
the viscosity dependence of flow distance in these devices for possible future work with viscous
samples like blood.

Figure 2.4. Effect of solution viscosity on the flow distance of 100 ng/mL (X) and 1.0 µg/mL (O) streptavidin
solutions in biotin-modified 17 µm deep and 58 µm wide channels with a 0.5 mm PDMS top layer. Flow distance is
only affected above a threshold viscosity of ~2 cP, corresponding to 24% glycerol.
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The effect of PDMS cover layer thickness on the flow distance was also studied with all other
parameters held constant. Figure 2.4 shows the influence of different PDMS top layer
thicknesses on the flow distance for 1.0 µg/mL streptavidin in biotin-modified channels. The
flow distance decreases at a slower rate as PDMS layer thickness is reduced, approaching an
asymptote around 0.45 mm cover layer thickness. I attribute the shorter flow distances for
thinner cover layers to the reduced force needed to deflect the cover layer and constrict the first
few millimeters of the channel, resulting in more rapid constriction and hence shorter capillary
flow time and distance. The leveling off observed approaching 0.45 mm thickness may occur
because forces exerted in the channel by capillary flow may start to contribute to constriction at
these shallower depths, leading to similar flow times and distances. From the data obtained, I
conclude that cover thickness allows control of the flow distance, and thus this parameter can
adjust dynamic range or limit of detection.

Figure 2.5. Effect of PDMS layer thickness on the flow distance for 1.0 µg/mL streptavidin in biotin-modified 17
µm deep and 58 µm wide channels. Flow distance decreases asymptotically as PDMS layer thickness is reduced.
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I explored the correlation between flow distance and streptavidin concentration for two different
channel heights. A plot of flow distance for various streptavidin solution concentrations in
biotin-modified 13 µm tall channels is given in Figure 2.5A. The plot shows a linear relationship
between the logarithm of streptavidin concentration and flow distance, along with a good R2
value of 0.95. A different set of experiments was carried out on biotin-modified 17 µm tall
channels (Figure 2.5B) and likewise showed a linear relationship with an improved R2 value of
0.98 and less data scatter than in the 13 µm tall channels. Also, improved assay sensitivity was
observed for deeper versus shallower channels, with a 40% increase in the magnitude of the
calibration curve slope. The linear relationship between logarithm of streptavidin concentration
and flow distance across a broad swath of concentrations in different channel heights highlights
the wide dynamic range for this method. The lowest quantified streptavidin concentration was
1.0 ng/mL, with flow distances of ~100 mm for 13 µm tall channels and ~130 mm for 17 µm tall
channels, with potential to detect lower streptavidin concentrations using longer channels. This
very low detection limit compared to the ~0.2 µg/mL protein detection limits in paper-based
assays17, 23 and excellent quantitation capability marks an important improvement in performance
for simple, rapid and inexpensive assays.
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Figure 2.6. Flow distance traveled as a function of streptavidin concentration in biotin-modified microchannels (58
µm wide) of two different heights, with a 0.5 mm thick PDMS top layer. (A) 13 µm deep channels. (B) 17 µm deep
channels.

I have evaluated and eliminated several plausible explanations for the observed flow behavior
that do not involve channel constriction. I measured contact angles of solutions of different
streptavidin concentrations (1 ng/mL–100 µg/mL) on b-BSA coated PDMS to be 25-26°. Thus,
the mechanism of flow stoppage is clearly not linked to concentration-dependent changes in
surface wettability or tension. In addition, flow experiments with buffer solutions lacking
streptavidin were performed in biotin-modified 13 µm tall PDMS microchannels with 0.45 and
0.5 mm cover layers. These solutions flowed the entire channel length, indicating that the flow
stoppage was not due to any pressure drop or channel constriction caused by capillary action.
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Finally, flow was unaffected by non-specific adsorption, as streptavidin solutions from 1 ng/mL–
100 µg/mL in 13 µm tall channels coated with BSA (lacking biotin) flowed the entire channel
distance. Thus, non-specific adsorption, which is a significant problem for conventional
immunoassays, appears not to play a major role in our “flow valve” devices, showing promising
potential for extension to other assay systems.

I further explored the mechanism of flow stoppage via channel closure using fluorescent imaging.
After capillary flow of a solution containing streptavidin mixed with the unreactive small
molecule marker fluorescein in a biotin-coated channel, the fluorescence in the first 10 mm of
the microchannel was imaged to observe any differences due to constriction (Fig. 2.6A-B). Plots
of normalized fluorescence signal across the channel at different flow distances demonstrate a
significant, 3-fold increase in channel fluorescence (i.e., cross-sectional area) moving away from
the solution introduction point until the signal plateaus at around 6 mm flow distance, as shown
in Figure 2.6C. Importantly, control experiments wherein streptavidin was replaced by BSA and
similarly flowed with fluorescein (Fig. 2.6D-F) showed no appreciable change in channel crosssection over the same portion of the flow channel, clearly supporting a channel constriction
mechanism that is specific to biotin-streptavidin interaction. I hypothesize that once this initial
portion of the channel is constricted to a sufficiently small aperture, flow stops. Thus, the
capillary flow distance of the target solution depends on the time needed to close the first few
millimeters of channel enough for flow to cease, which will be a function of target concentration.
Hence, for future “flow valve” designs, only the first few millimeters of the channel need to be
modified with receptor, and deeper channels after the constriction zone could also be used in
designing assays without serpentine channels.
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Figure 2.7. Plots of background subtracted, normalized fluorescence signal and peak area in 13 µm deep biotinmodified channels as a function of channel position and flow distance to probe constriction. (A-B) Unlabeled
streptavidin (500 µg/mL) mixed with fluorescein sodium salt (80 ng/mL); signal (which scales with pathlength or
channel height) is lowest near the reservoir, rising gradually to a constant level at about 6 mm flow distance. (C)
Normalized peak area of unlabeled streptavidin versus flow distance is lowest near the reservoir, increasing to a
constant value at ~6 mm flow distance. (D-E) Unlabeled BSA (500 µg/mL) mixed with fluorescein sodium salt (80
ng/mL); signal is essentially constant along the flow distance. (F) Normalized peak area of unlabeled BSA versus
flow distance is approximately constant throughout the flow distance.

A key question regarding “flow valve” assays is the following: how can molecular-scale (~10 nm)
surface interactions translate into much larger, micrometer-dimension alterations in
microchannel cross section that affect flow? I believe that the answer can be found in the data in
Figure 2.6, coupled with the posited channel constriction mechanism illustrated at the bottom of
Figure 2.1. At the edges of the microchannels, where the curved regions meet the flatter bottom
segment (see Fig. 2.1), the channel height is around the ~10 nm molecular scale, such that
biotin–streptavidin crosslinking of the top surface to the bottom is possible. This interaction
would pull the top and bottom surfaces incrementally closer, enabling similar molecular-scale
crosslinking to occur moving inward toward the middle of the channel. As this interaction
39

progresses, the edges of the channel would be fully constricted, while the middle would remain
partially open (i.e., Fig. 2.1J-K). Importantly, the data in Figure 2.6A-B are indicative of exactly
this type of change in cross-sectional channel profile induced by streptavidin solution flow,
strongly supporting our hypothesized mechanism. In further support of surface intermolecular
interactions leading to channel constriction, I have carried out simple force calculations. A
typical surface density of b-BSA molecules is 6 x 1016/m2,24 while the force needed to unbind
one biotin–streptavidin molecular pair has been measured as 200-300 pN.25, 26 Hence, the force
per area exerted by biotin-streptavidin surface interactions would be at least 1.2 x 107 N/m2, or
1740 psi, which is over a factor of 100 greater than the 5-10 psi needed to completely close
similarly shaped PDMS microfluidic valves.21 Thus, I conclude that molecular-scale interactions
have sufficient force to induce channel constriction and that the occurrence of such interactions
from the edges toward the center of a microchannel is both plausible and consistent with the
channel imaging data I have obtained.

Several matters must be considered as I look toward extending this assay method beyond biotinstreptavidin. Receptors must recognize at least two distinct sites on the target to crosslink
channels. Streptavidin readily meets this criterion with four biotin binding sites. Polyclonal
antibodies or two different monoclonal antibodies to a target would recognize different epitopes
and should also cause receptor-mediated crosslinking of microchannels in response to an antigen
target. Additionally, hybridization of a target nucleic acid sequence to complementary surfaceattached single-stranded oligonucleotides should mediate microchannel closure. Are antigenantibody or base pairing interactions strong enough to develop “flow valve” assays? The
unbinding forces for target-receptor pairs have been studied by scanning probe microscopy, and
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were 200-300 pN25, 26 per biotin-streptavidin molecular pair. The measured unbinding force for a
single antigen-antibody pair is 50-60 pN,27-29 which is less than biotin-streptavidin by a small
factor of 3-6 that could likely be accommodated through adjusting device parameters. The
unbinding force for hybridized DNA oligonucleotides, depending on the sequence and number of
base pairs, ranges from 450 pN30 for 14-mer sequences to 2700 pN for 20-base-long hybridized
pairs.31 These published unbinding data affirm the likely feasibility of generalization of “flow
valve” systems beyond biotin-streptavidin measurements to nucleic acid hybridization and
antigen-antibody interactions.

2.4 CONCLUSIONS
I have demonstrated a detectorless microfluidic approach for quantifying target analytes through
simple visual inspection of capillary flow distance in a microchannel. I have identified and
characterized three important parameters (solution viscosity, PDMS cover layer thickness and
channel height) that affect the flow distance in these assays for the biotin-streptavidin model
system. In addition, I found a linear relationship between flow distance in biotin-modified
channels and logarithm of streptavidin concentration over a 100,000-fold range of concentrations.
Moreover, I identified and studied a plausible mechanism of channel constriction and how this
leads to concentration-dependent flow distances. Importantly, I have measured streptavidin
concentrations as low as 1 ng/mL using these microsystems, demonstrating low detection limits,
with potential for future improvement. “Flow valve” microfluidic devices show great promise for
simplified, low cost, but high performance chemical analysis that could be extended to antigen
and nucleic acid determinations. “Flow valve” systems are especially promising for POC testing
due to their portability, and detectorless and label-free quantitation.
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3. EVALUATION OF COVALENT SURFACE ATTACHMENT WITH AN ANTIGENANTIBODY SYSTEM

3.1 INTRODUCTION
3.1.1 Covalent Surface Attachment
Biomolecules such as proteins, nucleic acids, etc. are immobilized on surfaces made of glass,
silicon, PDMS or plastic by various methods depending on the surface, biomolecule properties,
buffer constituents, etc.1 This chapter focuses on protein attachment on surfaces. In Chapter 2, a
flow valve assay was developed using biotin-streptavidin, where the surface of PDMS
microchannels was functionalized with biotinylated BSA through non-specific adsorption of
BSA. A more robust and stronger method of biomolecule immobilization is by covalent surface
attachment. The surface is activated via reactive reagents and then covalent bonds are formed
between exposed functional groups of biomolecules and the surface, resulting in strong
attachment.2 An ideal surface for covalent biomolecule attachment should have minimal nonspecific adsorption, good chemical stability and a reactive moiety for biomolecule coupling.3
However, sometimes the immobilization itself poses a problem for maintaining biomolecule
activity, as in the case of random orientation of amine (NH2) groups on an antibody for example.
3.1.1.1 Non-covalent attachment and its limitations
Biomolecules can be immobilized on substrates by non-covalent attachment, as seen in Chapter 2
for example. Some non-covalent attachment methods include sol-gel encapsulation, polymer
entrapment and physical adsorption (van der Waals, hydrophobic and hydrogen bonding
interactions).4 Krupin et al.5 demonstrated protein sensing using straight long-range surface
plasmon waveguides and physisorbing bovine serum albumin on a carboxyl-terminated self44

assembled monolayer on gold. Zhao et al.6 studied adsorption of antibodies on silica particles
using spectroscopic ellipsometry and neutron reflection under changing conditions of pH and salt
concentrations and found the antibodies to adopt a ‘flat on’ orientation with both Fab and Fc
attached to the surface, with comparable antigen-binding capabilities. Although simple to
perform, non-covalent attachment can lead to inactivation of the immobilized biomolecule by
denaturation or steric occlusion and can also lead to high background signal due to non-specific
surface fouling.4

3.1.1.2 Random surface attachment of proteins
In principle, several functional groups of amino acids in proteins, such as amine (–NH2),
sulphhydryl (-SH), carboxyl (-COOH) and hydroxyl (–OH), can be chemically coupled with
derivatized surfaces via known bioconjugate techniques.1 Generally, this approach makes the
immobilization points random, since the attachment can occur through one of many different
residues, thus creating heterogeneity in the orientation of a population of immobilized proteins.2
The functional groups used for attachment can be found in several portions of the biomolecule as
shown in Figure 3.1, where different antibody amine groups are attaching to a functionalized
surface with varied orientations. Thus, antigen-antibody binding can be reduced because the
antibody may lose biological activity due to linkage formations on active sites (Figure 3.1C).7

45

Figure 3.1. Glutaraldehyde-functionalized surface (A) attaches antibody (B) by random immobilization. Antibody
can attach via (C) an amine group (1) at the Fab site, (D) an amine group (2) at the Fc position, or (E) an amine
group (3) on the tail of the heavy chain, leading to variable orientations of the attached antibody.

3.1.1.3 Oriented surface attachment
Chemical attachment can be guided in an orderly manner for oriented immobilization to avoid
denaturation of the attached biomolecule.8 By selectively attaching a predetermined site of the
biomolecule to a surface, oriented immobilization can be achieved. For example, attachment of
reduced antibodies leads to oriented receptor placement9 and greater density of functional active
sites (Figure 3.2A). Another example of immobilization in an oriented manner is through protein
A adsorption or bonding to surfaces followed by binding of immunoglobulin G (IgG) (Figure
3.2B).10 In a nucleic acid-based system, attachment of derivatized oligonucleotides to a surface
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will lead to oriented immobilization as the reactive group can be on either the 5’ or the 3’ end
(Figure 3.2C).

Figure 3.2. Oriented surface attachment. (A) Maleimide-activated surface (1) attaches reduced antibody (2) and
leads to oriented antigen-binding site placement (3). (B) Protein A-activated surface (1) attaches antibody (2) by the
Fc region (3) which leads to oriented receptor placement. (C) Glutaraldehyde-activated surface (1) attaches aminemodified oligonucleotide (2) by the 3’-end which orients the 5’-end for further interaction (3).

3.1.1.4 Silanization/Functionalization of plasma-oxidized PDMS
Poly(dimethylsiloxane) or PDMS is a widely used material in the field of microfluidics due to its
low cost, ease of fabrication, oxygen permeability and optical transparency.11 A considerable
amount of work on modification and functionalization of PDMS surfaces has been undertaken by
several research groups.11-14 However, PDMS is hydrophobic and, hence, the unmodified surface
is poorly wetted and is prone to attracting bubbles in aqueous medium.12 To overcome this
limitation, the PDMS surface is usually plasma-oxidized to generate silanol groups thus
rendering

it

more

hydrophilic.15 Plasma-oxidized
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PDMS

can

be

treated

with

3-

aminopropyltrimethoxysilane, 3-mercaptopropyltrimethoxysilane or other silanes16 to form a
reactive surface to which receptors can be attached. After this modification, a number of
attachment processes are possible. For example NH2-containing molecules can be linked by
direct reaction with glutaraldehyde-treated NH2-modified PDMS, with use of a bifunctional
coupling agent such as sulfo-SMCC17 to react with SH-silanized PDMS, or through reaction with
carbodiimides such as EDC18 and a COOH-terminated surface. Alternatively, NH2-modified
PDMS can be reacted with SH groups (e.g., reduced antibodies or SH-modified oligonucleotides)
using sulfo-SMCC.

3.1.2 Working with thymidine kinase as a model antigen-antibody system
3.1.2.1 Various forms
Thymidine kinase (ATP: thymidine 5’- phosphotransferase, EC 2.7.1.21 or TK)19 is a salvage
enzyme found in most living cells and is involved in DNA precursor synthesis.20 It
phosphorylates thymidine to thymidine monophosphate (dTMP) which is further phosphorylated
to thymidine diphosphate (dTDP) and triphosphate (dTTP).21 TK occurs in two forms
(isoenzymes) in mammalian cells: TK1 and TK2. TK1 is a cytosolic enzyme and functions in the
supply of thymidine nucleotides for nuclear DNA synthesis (cell-cycle dependent),22 whereas
TK2 is present in the mitochondria and contributes to the supply of pyrimidine phosphates for
mitochondrial DNA synthesis (cell-cycle independent).22 Elevated levels of TK1 have been
found in several tumor types.23
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3.1.2.2 TK1 as a serum biomarker
TK1 expression is highly regulated in mammals with respect to the cell cycle.24 Enzyme activity
increases in the late G1 phase, reaches peak values in the S phase and then decreases in the M
phase.24 Accordingly, high levels of TK1 are found in proliferating and malignant cells and
tissues,25 serving as diagnostic biomarkers of tumors. Cellular TK1 exists in various forms; the
dimeric form is 50 kDa, the tetrameric form (activated by ATP) is 100 kDa and several
oligomeric forms also exist.24 In serum, total measured TK1 activity corresponds to a molecular
weight range of 300-720 kDa.24 Thus, serum TK1 probably exists in complexed forms bound to
other proteins.24 Due to its complexation in serum, development of assays for TK1 quantitation
has been difficult.

In healthy individuals, serum TK1 is present in sub-picomolar concentrations, but in patients
with malignant disease, TK1 levels rise significantly.24 Serum TK1 levels have been measured
by incubating the serum sample with a radioactive substrate analogue (Prolifigen TK-REA),24
and this radioactive assay has been used to predict relapse of disease and for follow-up therapy.
A non-radioactive method for measuring TK1 activity (TK Liaison, DioSorin) has also been
used,26 which provides valuable information in patients with leukemia and lymphoma.
Furthermore, antibodies against human TK1 have been developed and serum TK1 has been
quantified in different cancer types such as bladder carcinoma,27 breast carcinoma28 and lung
cancer.29
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I have developed flow valve assays for TK1 quantitation using a similar process to that described
in Chapter 2. Polyclonal anti-TK1 antibodies have been attached to microchannel surfaces and
capillary flow distances for different recombinant TK1 concentrations have been measured.
Working conditions for performing flow valve assays have been obtained, along with checking
the uniformity of anti-TK1 attachment to the channel surface after various treatment steps.

3.2 EXPERIMENTAL METHODS
Mold preparation and PDMS device fabrication followed the same procedures as in Section 2.2.
3.2.1 Surface attachment
3-aminopropyl-diisopropylethoxysilane (APDIES, Gelest, Morrisville, PA, 1-5% v/v in methanol)
was filled via a combination of capillary action and/or vacuum in plasma-bonded PDMS
microchannels (Figure 3.3A) of various heights (7-18 µm). The silane was allowed to attach
covalently to the PDMS channel walls for 30-60 min, leaving exposed amine groups (see Figure
3.3B). Then the APDIES solution was removed and the channels were flushed with phosphate
buffered saline (PBS, 10 mM, pH 7.2) to remove unattached material. Next, PBS was aspirated
from the channels and glutaraldehyde solution (Sigma-Aldrich, St. Louis, MO, 0.5-8% v/v in
water) was added to the channels and incubated for 30-60 min to react with APDIES amine
groups at one end, leaving the other aldehyde free for subsequent attachment of aminefunctionalized biomolecules (Figure 3.3C) such as anti-TK1 (Bethyl Laboratories, Montgomery,
TX). Then the glutaraldehyde solution was removed and channels were once again flushed with
PBS to remove unattached material. Then, PBS was aspirated from the channels and 2 µL of a 2
mg/mL anti-TK1 solution in PBS buffer was filled in the channels by capillary action/vacuum
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followed by 1 hour incubation (Figure 3.3D). After this, the same draining and rinsing with PBS
were followed as above to remove unattached receptors. This was followed by aspiration of PBS
from the channels. Finally 1 µL of TK1 target solution of specified concentration in PBS was
pipetted into the reservoir. The flow distance of the target solution in the microchannel was
measured with a ruler, and photographs were obtained with a digital camera.

Figure 3.3. Surface attachment of labeled anti-TK1. Thick black lines represent PDMS channel walls. (A) Plasmaoxidation produces silanol groups on the channel surface. (B) Treatment with APDIES generates amine groups on
the surface. (C) Amine groups react with glutaraldehyde. (D) Anti-TK1 is immobilized on the channel surface via
glutaraldehyde.

3.2.2 Checking uniformity of receptor attachment using fluorescence imaging
Fluorescently labeled anti-TK1 (2 mg/mL) was allowed to flow in 13 µm tall amine-derivatized
microchannels. Fluorescence detection was done as in Section 2.2.4, resulting in fluorescent
signal of anti-TK1 at different locations in the channel.

3.3 RESULTS AND DISCUSSION
Experiments on TK-1 were conducted to evaluate the surface attachment method and obtain flow
assay results. I determined working concentrations and incubation times for silane (APDIES) and
cross-linker (glutaraldehyde) for flow valve assays. Also, under these working conditions I
confirmed the uniformity of anti-TK1 receptor attachment on a microchannel using fluorescence
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imaging. In addition, I measured flow distances for different TK1 target concentrations in
antibody-attached microchannels.
3.3.1 Determining working conditions
APDIES and glutaraldehyde were used to attach anti-TK1 to the microchannel surface. In 7-8
µm tall plasma-oxidized channels, a 1% APDIES solution flowed at a non-linear rate with flow
stopping even with applied vacuum, probably due to the viscous nature of the silane solution and
the shallow channels. Therefore, the channel height was raised to 13 µm, different APDIES
concentrations (1%, 2%, 5% and 10%) were flowed in plasma-oxidized channels, and the flow
rate through the channel was observed. Whereas the 10% and 5% APDIES resulted in flow
stoppage either during APDIES treatment or at later derivatization steps, the 1% and 2%
APDIES flowed through the channel at a uniform rate without any stoppage in the flow.
Subsequent treatment with 5% glutaraldehyde and 2 mg/mL anti-TK1 were possible in channels
derivatized by 1% or 2% APDIES concentrations. These devices were then tested by flowing
100 µg/mL TK-1 in PBS through the channels. In channels treated with 1% APDIES in replicate
tests, the flow distances for 100 µg/mL TK1 were 57 mm, 100 mm and 125 mm (~40% RSD),
but replicates in channels treated with 2% APDIES were more reproducible (<30% RSD). Hence,
2% APDIES was chosen as the working concentration for assays. Subsequent optimization on
DNA attachment (Chapter 4) established 8% glutaraldehyde as the best concentration, which was
used in all experiments going forward.
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3.3.2 Evaluation of anti-TK1 attachment on microchannels
I checked for uniformity of anti-TK1 attachment on the channel surface using the working
conditions (2% APDIES and 8% glutaraldehyde) derived above. Figure 3.4 shows the
fluorescence signal as a function of distance from the reservoir in 13 µm tall plasma-oxidized
channels treated with 2% APDIES, 8% glutaraldehyde and 2 mg/mL anti-TK1 solution. The plot
shows a line almost parallel to the x-axis indicating that the fluorescence signal is uniform along
the microchannel. This result shows that anti-TK1 is attached to the channel surface reasonably
uniformly after these treatment steps. Hence, the conditions obtained for the surface attachment

Background-subtracted fluorescence

are sufficient and can potentially be applied to other systems for receptor immobilization.

Distance from channel entrance (mm)

Figure 3.4. Background-subtracted fluorescence signal versus distance from the channel entrance in 13 µm channels
derivatized with labeled anti-TK1. The rinsing and draining steps with PBS were followed according to Section
3.2.1 to get rid of unattached receptors from the channel before fluorescence imaging. Data points represent average
fluorescence signal and error bars represent standard deviation in fluorescence signal.

3.3.3 Flow assay results
I explored the correlation between flow distance and TK1 concentration for different channel
heights. In less than 13 µm channel heights, there were rinsing/draining problems before addition
of TK1, probably because the channel height was too small for carrying out the multiple
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treatment steps for channel surface functionalization, thus leading to blockage issues. A plot of
flow distance for three replicates of various TK1 solution concentrations in anti-TK1-modified
13 µm tall channels is given in Figure 3.5. The plot shows a linear relationship between the flow
distance and logarithm of TK1 concentration from 1 ng/mL-100 µg/mL. The lowest TK1
concentration detected was 1 ng/mL, indicating good detection limits for the system. These
results are also consistent with experiments in Chapter 2 (Figure 2.5). Compared to Figure 2.5A,
the linear fit has more scatter (R2 = 0.944 versus 0.951) and a longer flow distance (155.5
intercept versus 86.6 in Figure 2.5A). This is probably because of the weaker force of interaction
between TK1 and anti-TK1 compared to the force of interaction between biotin and
streptavidin30-31 (Chapter 2) thus leading to greater variability in the flow distances for replicate
runs of the same TK1 target concentration. From the results obtained, it is clear that antigenantibody interaction in my system is strong enough for channels to constrict sufficiently such that
the flow distance of target solution depends on the TK1 concentration. Hence, flow valve assays
can be carried out with other antigen-antibody pairs specific to disease diagnosis in the future.

Figure 3.5. Flow distance traveled as a function of logarithm of TK1 concentration in 13 µm tall antiTK1-modified
channels. A linear correlation is obtained, best fit equation: y = -21.8±1.3 log(x) + 155.5±4.0. Control (buffer only)
is shown as squares.
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I also verified that the system is specific for TK1 in the antibody-functionalized microchannels.
In a control experiment, microchannels (13 µm tall), were functionalized with anti-streptavidin
instead of anti-TK1 using the same protocol described in Section 3.2.1. Then, different
concentrations of TK1 solutions (1 ng/mL-100 µg/mL) were added and the flow distances were
all ~160 mm, approximately the same as buffer solution lacking TK1, indicating specificity to
the TK1 antigen-antibody pair.

3.4 CONCLUSIONS
I demonstrated the detection of a model cancer biomarker, TK1, in flow valve devices. I
determined initial device fabrication and surface modification methods for carrying out flow
assays. Using these conditions, I also verified receptor attachment on the channel surface using
fluorescence imaging and flow assay results. In addition, I demonstrated the visual detection and
quantification capability of my system to determine an antigen target, TK1, in buffer solution.
The flow distance in anti-TK1-modified channels correlated linearly with logarithm of TK1
concentration over a range of concentrations, with a ~1 ng/mL TK1 detection limit. My methods
can potentially be used for other antigen-antibody systems specific to disease diagnosis. Hence,
this detectorless system has great potential for point-of-care diagnosis and can be expanded to
other target systems in the future.
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4. MICROFLUIDIC DEVICES FOR LABEL-FREE AND NON-INSTRUMENTED
QUANTITATION OF UNAMPLIFIED NUCLEIC ACIDS BY FLOW DISTANCE
MEASUREMENT †
4.1 INTRODUCTION
Biomarkers are disease indicators which can be found in body fluids such as blood, saliva or
urine and can indicate the disease state and/or progression characteristics.1-2 The measurement of
biomarkers is playing a growing role in early detection of disease, enabling improved treatment.
Various biomarkers, including proteins, carbohydrates, lipids, hormones, metabolites and nucleic
acids have been correlated with physiological responses to disease, injury, stress, etc.3

One class of analysis systems for biomarkers includes high performance benchtop instruments
such as mass spectrometers (MS),4-5 liquid chromatography coupled to MS,6-7 capillary
electrophoresis coupled to MS,7 Raman spectroscopy,8 and nuclear magnetic resonance
spectroscopy.9 On the other hand, simplified systems include paper-based microfluidics,10-13
blood glucose monitors,14 lateral flow immunoassays,15 and other point-of-care systems.16 Many
benchtop instruments have desirable performance characteristics such as good detection limits,
accuracy, specificity, quantitation and/or multiplexing, but the instrumentation is usually
expensive and non-portable. In contrast, point-of-care systems are generally inexpensive and
quick but lack several desirable performance characteristics such as good detection limits,
quantitation capabilities (except for glucose monitoring14), and multiplexing.

Adapted with permission from D. Chatterjee, D. S. Mansfield and A. T. Woolley, Analytical Methods,
2014, accepted for publication.

†
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One important class of nucleic acid biomarkers is microRNA (miRNA), 19-24 nucleotide long,
noncoding RNA that blocks translation of messenger RNA and, hence, plays a critical role in cell
function.17-18 MiRNAs were first described in 1993 by Lee and collegues.19 Differential
expression of miRNAs in many disease states combined with their presence in serum, plasma
and other body fluids, makes them promising biomarkers in early detection, classification, or
prognosis of various illnesses including cancer,20-21 diabetes,22 kidney disease,23-24 and liver
disease.25 For example, specific miRNAs are up- or down-regulated in cancer and thus have
promise as biomarkers for cancer classification.17 Mir-141 has elevated levels in the blood of
prostate cancer patients, while mir-25 and mir-223 have increased serum levels in lung cancer
patients compared to controls.17 Moreover, differential expression of mir-126 and mir-182 in
urine identified bladder cancer,26 while mir-125a and mir-200a were detected at reduced levels in
the saliva of oral squamous cell carcinoma patients compared to healthy controls.27 Furthermore,
mir-29a, mir-181a and mir-652 are potential breast cancer biomarkers,28 while mir-21, mir-146a
and mir-148a show promise to predict lymph node metastasis in gastric cancer.29

Accurate measurement of miRNA levels is important, but the intrinsic characteristics of miRNAs
such as low levels (fg/mL-pg/mL), small size, sequence similarity and difficulty in selective
amplification make detection challenging.30 Despite the difficulty, some methods have been
developed for miRNA measurement. Quantitative reverse transcription PCR (qRT-PCR), which
is the gold standard for sequence-specific RNA quantitation, does not work for miRNAs since
they are about the same length as standard PCR primers.31 However, modifications of qRT-PCR
using stem loop primers combined with TaqMan probes,30 enable miRNA measurement with
good dynamic range, 1000-fold better sensitivity than hybridization methods and reasonable
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target specificity.30 Yet, this method needs probes, stem-loop primers and a reverse transcription
step, all of which increase complexity and assay time. An amplification-based enzymatic
bioluminescence miRNA assay32 provides 10 pg/mL detection limits, but the use of enzymes and
their costs are disadvantages. In-situ hybridization with locked nucleic acid probes33 can
determine native locations of miRNAs inside cells and tissues, but requires a fluorescence
microscope, and suffers from low throughput and high background signal. Microarray
hybridization-based methods34 for miRNA profiling offer high throughput, but require a labeling
step for detection, thus increasing complexity and cost. Liu et al.35 recently detected miRNAs
through graphene fluorescence and switch-based cooperative amplification, resulting in a 11 fM
(~4 fg/mL) limit of detection; however, this method introduces complexity through amplification
and labeling. Label-free miRNA detection methods involving nanopores36 and surface plasmon
resonance37 have also been developed, with detection limits in the mid-fM range. Although
sample preparation is simplified because labeling is not needed, sophisticated instruments and/or
complex data interpretation are required, thus hindering their use in simple, point-of-care
diagnostic settings.

I have developed a novel, label-free, sequence-specific nucleic acid quantitation method wherein
the concentration is correlated with capillary flow distance of target solution in receptor-coated
microfluidic channels. Devices are made in an elastomer, poly(dimethylsiloxane) (PDMS), that
has microfluidic channels covalently derivatized with oligonucleotide receptors that are
complementary to the target. Specific hybridization of target to receptors allows constriction
through cross-linking of the top and bottom channel surfaces, as illustrated schematically in
Figure 4.1. This concentration-dependent constriction relates target concentration with the
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capillary flow distance. Thus, target concentration can be determined readily from the capillary
flow distance, which is easily measured through visual inspection. I have studied DNA
analogues of miRNAs and found a flow distance dependence on target concentrations from 10
µg/mL to 10 pg/mL in both buffer and synthetic urine. Furthermore, flow time in addition to
flow distance is correlated with target concentration. My approach offers excellent detection
limits (10 pg/mL) and can discern single-base mismatches. Finally, I have analyzed DNA
analogues of miRNAs linked to kidney disease and prostate cancer in synthetic urine samples
and detected these analytes near clinically relevant levels. My novel quantitation method’s
simplicity and cost effectiveness combines performance, selectivity and speed, thus
demonstrating excellent potential for wide application in point-of-care nucleic acid biomarker
diagnostics.

Figure 4.1. DNA sensing platform. (A) Cross-section view of an unconstricted channel. (B) Cross section of a
partially constricted channel caused by complementary target sequence hybridization with surface receptors. (C)
Zoom view of the rectangle in A, showing an unconstricted channel before flowing target; not drawn to scale in the
vertical direction. (D) Zoomed in view of the rectangle in (B), showing constriction from target hybridization.
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4.2 EXPERIMENTAL SECTION
Mold preparation and PDMS device fabrication followed nearly the same procedures I described
earlier (Chapter 2),38 but using a different positive photoresist, AZ4620 (AZ Electronic Materials,
Branchburg, NJ). The microchannels in the devices used for flow distance experiments were 11
µm tall and 58 µm wide with a 0.5 mm PDMS top layer thickness. Other channel heights (7-18
µm) were used for initial surface modification optimization. All DNA oligonucleotides were
obtained from Operon Biotechnologies (Huntsville, AL); names and sequences are given in
Table 4.1.
Table 4.1. DNA oligonucleotide names and sequences (from 5’ to 3’); [C3Amino] = primary amine group at the end
of a 3 carbon spacer, [AminoC6] = primary amine group at the end of a 6 carbon spacer.
DNA Oligonucleotide Name

Sequence

Model receptor 1

CCAACTATCAA[C3Amino]

Model receptor 2

[AminoC6]CAACTCCATCA

Model target

TTGATAGTTGGTGATGGAGTTG

Total mismatch

CATAACCGATATATTCGGTCGC

th

6 base-3’ end mismatch

TTGATAGTTGGTGATGAAGTTG

th

6 base-5’ end mismatch

TTGATTGTTGGTGATGGAGTTG

2nd base-5’ end mismatch

TAGATAGTTGGTGATGGAGTTG

11th base-5’ end mismatch

TTGATAGTTGTTGATGGAGTTG

Mir-200c-3p receptor 1

CGGCAGTATTA[C3Amino]

Mir-200c-3p receptor 2

[AminoC6]TCCATCATTACC

Mir-200c-3p

TAATACTGCCGGGTAATGATGGA

Mir-107 receptor 1

ACAATGCTGCT[C3Amino]

Mir-107 receptor 2

[AminoC6]TGATAGCCCTGT

Mir-107

AGCAGCATTGTACAGGGCTATCA
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4.2.1 Procedure for experimentation
The basic protocol for surface modification in the DNA sensing platform is outlined
schematically in Figure 4.2 and described below. A surface-modification reagent, 3aminopropyl-diisopropylethoxysilane (APDIES, Gelest, Morrisville, PA, 1-5% v/v in methanol),
was introduced via a combination of capillary action and/or vacuum in plasma-bonded PDMS
microchannels of 7-18 µm heights. The silane was allowed to attach covalently to the PDMS
channel walls for 30-60 min, leaving exposed amine groups (see Figure 4.2B). Then the APDIES
solution was removed and the channels were flushed with phosphate buffered saline (PBS, 10
mM, pH 7.2) to remove unattached material. Next, PBS was aspirated from the channels and
glutaraldehyde solution (Sigma-Aldrich, St. Louis, MO, 0.5-8% v/v in water) was added to the
channels to react with the APDIES amine groups, as seen in Figure 4.2C, for 30-60 min. Then
the glutaraldehyde solution was removed and channels were once again flushed with PBS. Some
initial experiments with (3-glycidyloxypropyl)trimethoxysilane (GOPS, Sigma-Aldrich, 1-10%
v/v in methanol) instead of APDIES were also conducted using the same protocol as above but
without glutaraldehyde reaction with the silanized surface. Next, PBS was aspirated from the
channels and 2 µL of a 2 mg/mL amine-modified DNA oligonucleotide solution (50/50 mixture
of two receptor sequences in 10 mM PBS) was introduced into the channels by capillary action
followed by 1 hour incubation to react with the free aldehyde in glutaraldehyde. After this,
channel emptying followed by rinsing with PBS were done as above. During all of the incubation
steps, the devices were stored in a humidified ambient atmosphere to prevent drying. After
emptying the channel by applying vacuum, 1 µL of DNA target solution of specified
concentration in PBS or simulated urine (VWR, West Chester, PA) was pipetted into the
reservoir. The flow distance of the target solution in the microchannel was measured with a ruler,
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and photographs of the devices were obtained with a digital camera. Experiments for
determining flow distance as a function of time were also performed with buffer (no DNA) or
target solutions; flow distance was measured every 10 seconds until the fluid receded back to the
sample introduction point. Experiments with mismatched sequences (see Table 4.1) of specified
concentration in PBS were conducted under the same protocol as for the complementary DNA
target. Also, experiments were conducted with DNA analogues of miRNA, mir-200c-3p and mir107, in PBS and simulated urine with their respective amine-modified receptors attached to
channel surfaces (see Table 4.1).

Figure 4.2. Surface attachment of oligonucleotide receptors. Thick vertical lines represent PDMS channel wall. (A)
Plasma-oxidized channel has silanol groups on the surface. (B) Treatment with APDIES generates amine groups on
the surface. (C) Amine groups react with glutaraldehyde. (D) Amine-modified oligonucleotides are immobilized on
the channel surface via glutaraldehyde.

4.3 RESULTS AND DISCUSSION
I studied nucleic acid sensing in a flow distance microfluidic platform. I measured the flow
profiles of target and control (buffer) solutions as a function of time in the derivatized
microchannels. In addition, I characterized the maximum flow distances for different
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concentrations of various DNA oligonucleotides, including a complementary DNA target
sequence, single-base and fully mismatched sequences, and DNA analogues of miRNA targets.
Figure 4.3 shows schematics as well as photographs of microchannels before and after the
addition of target solutions. Figure 4.3A shows an unfilled channel that is clearly visible in the
photograph, while Figure 4.3B shows a microchannel partially filled with buffer solution that can
be easily distinguished from the unfilled portion. This flow distance can readily be determined
by visual examination. Figures 4.3C and 4.3E show shorter flow distances for 10 µg/mL model
target DNA concentrations in buffer and synthetic urine respectively, while Figures 4.3D and
4.3F show longer flow distances for 10 ng/mL (lower concentration) model target in these same
matrices. These results agree with my expectation that higher target concentrations cause more
rapid channel constriction, which leads to shorter flow distances, while lower target
concentrations result in slower channel constriction that yields longer flow distances, as I showed
previously (Chapter 2).38
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Figure 4.3. Flow assay data. Each panel has a device schematic on top and a device photograph beneath with white
arrows showing the flow direction. (A) Empty channel is readily visible. (B) Channel with buffer solution lacking
target DNA flows 134 mm; the empty channel segment is distinct from the filled portion. (C) 26 mm flow distance
for 10 µg/mL model target in buffer. (D) 66 mm flow distance for 10 ng/mL model target in buffer. (E) 16 mm flow
distance for 10 µg/mL model target in synthetic urine. (F) 61 mm flow distance for 10 ng/mL model target in
synthetic urine.

In initial experiments I derivatized microchannels with GOPS in an effort to attach aminemodified DNA receptors to plasma-oxidized microchannels. In a 13 µm tall channel
functionalized with 1% GOPS and treated with model receptors 1 and 2 (see Table 4.1), a high
concentration (700 µg/mL) of model target solution travelled 130 mm, a much longer flow
distance than I observed for similar concentrations and channels in earlier work involving biotinstreptavidin.38 I hypothesized that perhaps either a higher GOPS concentration or shorter channel
height would decrease the flow distance. However, increasing the GOPS concentration to 8% or
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reducing the channel height to 7 µm still resulted in a 130-140 mm flow distance for 700 µg/mL
solutions of model target. Furthermore, different incubation times (30-180 min) for GOPS were
tried, but likewise yielded similar flow distances for the same concentration of model target.
From these experiments, I concluded that GOPS and amine-linked DNA coupling did not work
well in my system, possibly because the reactive epoxy ring had been partially deactivated
before exposure to DNA by ring opening in the presence of water or methanol –OH groups.
Another reason for poor results with GOPS could be that it is a tri-alkoxy silane that can form
branched or cross-linked structures that result in multiple layers and poorer uniformity in the
coating.

Given the difficulties encountered with GOPS, I also tried surface functionalization with
APDIES along with a cross-linker (glutaraldehyde) for receptor attachment. APDIES has just
one surface-reactive alkoxy functional group, which results in channel coating with a maximum
of a monolayer of silane. In 13 µm tall channels modified using 2% APDIES and glutaraldehyde
concentrations of 2%, 5% and 8%, the flow distances for 1-10000 ng/mL model target solution
are given in Table 4.2. I observe two trends in the data: first, for a given concentration of model
target, the flow distance decreases with increasing concentration of the glutaraldehyde crosslinker used in derivatization; second, more marked dependence of flow distance on concentration
is observed with increasing glutaraldehyde concentrations. I hypothesize that increased numbers
of receptor attachments on the channel surface with higher cross-linker concentrations provide
more target-receptor interaction, resulting in more rapid channel constriction and shorter flow
distances. With 2% glutaraldehyde, there is little flow distance dependence on concentration.
With 5% and 8% glutaraldehyde, there is some flow distance dependence on concentration, and
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the change in flow distance for each 10-fold concentration change is greater for 8%
glutaraldehyde. Thus, 8% glutaraldehyde solution was used for surface derivatization because of
the greater sensitivity of flow distance to changes in DNA concentration. I note that solutions
with glutaraldehyde concentrations over 8% were so viscous that flow through 13 µm tall
channels during successive steps was irreproducible, making further increases in glutaraldehyde
concentration impractical.
Table 4.2. Flow distances for 1-10000 ng/mL model target in buffer in channels derivatized with 2% APDIES,
followed by 2%, 5% or 8% glutaraldehyde, and then model receptors 1 and 2. Flow distance for each entry in the
table represents a single experiment.

Model [Target]
(ng/mL)
1
10
100
1000
10000

[Glutaraldehyde]
5%
134 mm
125 mm
119 mm
80 mm
74 mm

2%
145 mm
125 mm
136 mm
118 mm
100 mm

8%
133 mm
119 mm
98 mm
62 mm
47 mm

In 13 µm tall microchannels modified with receptors, 1 ng/mL model target solutions in buffer
flowed distances close to those of buffer lacking DNA (130-140 mm). I found that microchannel
heights of 11 µm allowed us to determine DNA target concentrations even lower than 1 ng/mL,
so this channel height was used in subsequent work. Experiments were conducted to determine
flow distance as a function of time for solutions (with or without DNA) travelling through
receptor-coated, 11 µm tall microchannels. Figure 4.4 shows the flow distances for buffer
(lacking DNA) and model target DNA (1 µg/mL and 1 ng/mL) in buffer, as a function of flow
time in microchannels coated with model receptors 1 and 2. The flow distance for buffer, which
does not interact with receptors, increases with flow time until reaching a plateau at 123 mm
flow in ~180 seconds. In contrast, the model target in solutions interacts with the surface
68

receptors which constricts the channel (Figure 4.1B and 4.1D), and slows the flow velocity. Thus,
1 ng/mL target takes ~450 seconds to travel 80 mm where it stops, compared to ~60 seconds for
buffer solution to travel the same distance. Also, 1 µg/mL model target takes ~180 seconds to
travel 32 mm where it stops, versus 20 seconds for buffer and 90 seconds for 1 ng/mL model
target to travel the same distance. In all experiments after flow stops, the fluid position is
maintained for another ~3 min, after which the liquid recedes back to the sample introduction
point due to evaporation. I note that this 3 min “plateau” in flow gives ample time for distance
measurement. Figure 4.5 shows a plot of this maximum flow distance as a function of flow time
for different model target DNA concentrations. Lower model target concentrations have greater
maximum flow distances and flow times. Thus, flow time, in addition to flow distance,38 could
be used to determine the concentration of target in a solution flowed in my devices.

Figure 4.4. Flow distance as a function of flow time for buffer lacking DNA and two different model target
concentrations in microchannels coated with model receptors 1 and 2. The flow distance for buffer increases with
flow time until reaching a plateau in ~3 min; 1 ng/mL target takes 8 min to travel ~80 mm where it plateaus and 1
µg/mL target takes ~3 min to travel ~30 mm where it plateaus.

69

Figure 4.5. Maximum flow distance as a function of flow time in microchannels coated with model receptors 1 and
2 for different model target concentrations in buffer; best fit equation: y = 7.79±0.38 x + 14.9±3.1, R2 = 0.956.

The mechanism of concentration dependent flow distance by channel constriction owing to
target-receptor interaction was covered in Chapter 2. Figure 4.4 along with some additional flow
experiments provide further insights into the mechanism. In Figure 4.4, buffer (lacking DNA)
travelled 123 mm and then stopped. The incomplete filling of the channel by buffer lacking
target is due to a combination of two effects. First, evaporation from the sample inlet reservoir
eventually removes all the liquid from the reservoir. Then, the surface tension of the liquid in the
channel causes the fluid to flow back to add liquid to the reservoir. When target solution is added
to a receptor-modified channel, the channel is constricted in the first few millimeters due to
target-receptor interaction (see Figure 2.6). Thus target solutions travel shorter distances than
buffer lacking target (as seen in Figure 4.4). The channel remains constricted when fluid recedes
after the maximum flow distance is reached in each test experiment in Figure 4.4. This is
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supported by flow experiments where the same target solution was added after evaporation and
traveled a shorter flow distance, which is probably due to further channel constriction upon
target addition the second time.

Experiments involving several mismatched sequences were done using 11 µm tall microchannels
coated with model receptors 1 and 2. Figure 4.6 shows the maximum flow distance as a function
of logarithm of DNA concentration for the model target and three mismatched sequences. For
the model target sequence, the flow distance has a linear correlation with the logarithm of target
concentration. The lowest detected model target concentration was 10 pg/mL with a mean flow
distance of 118 mm, appreciably less than the buffer (no DNA) mean flow distance (128 mm).
The total mismatch sequence flows greater distances (nearly the same as buffer, except for the 10
µg/mL solution) than all the other sequences, indicating that the surface-attached model
receptors 1 and 2 do not bind appreciably with the total mismatch sequence in solution flowing
through the channel. This result demonstrates the specificity of my system in distinguishing
between complementary and non-complementary sequences. Because of this significant
difference in flow properties, I decided to test the ultimate in sequence specificity: single-base
mismatches. Thus, I tested flow with oligonucleotides that differed from the target only at the 6th
position from the 5’ end or at the 6th position from the 3’ end. As seen in Figure 4.6, the
mismatched sequences had 10-20 mm longer average flow distances than the model target, but
shorter flow distances than the total mismatch at each concentration. These results also indicate
that flow distances for a base mismatched sequence can be differentiated from the model target
over a 100-fold concentration range. I also tested additional mismatched sequences (see Table
4.1 and Figure 4.7). These results show that the position of the base mismatch is important in
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generating a distinct flow distance from the complementary sequence. My results with
mismatched sequences clearly indicate that the binding of surface-attached receptors to target is
affected by a difference of just one base in the sequence, demonstrating that my approach can be
used to differentiate between single-base mismatch point mutations which are often the cause of
genetic disorders.

Figure 4.6. Maximum flow distance as a function of logarithm of DNA concentration for complementary and
mismatched sequences in microchannels coated with model receptors 1 and 2. Mismatches 6 bases from the 3’ or 5’
end of the model target have distinct flow distances from the complementary sequence.
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Figure 4.7. Flow distance as a function of logarithm of DNA concentration for complementary and mismatched
sequences in microchannels coated with model receptors 1 and 2. Base mismatches at the 2nd position from the 5’
end have distinct flow distances from the complementary sequence but those at the 11th position from the 5’ end
flow essentially the same as the complementary sequence.

Figure 4.8 shows flow distances in receptor 1 and 2 modified microchannels as a function of
logarithm of model target concentration in buffer and synthetic urine. A linear correlation is seen
between flow distance and logarithm of target concentration in both buffer and in synthetic urine,
which should enable direct quantitation from the easily measured flow distance. Moreover, the
linearity is maintained over a 106-fold range of concentrations, indicating a wide dynamic range.
The lowest concentration of target DNA detected is 10 pg/mL, indicating excellent detection
limits and a 100-fold improvement over what I achieved previously for biotin-streptavidin
(Chapter 2).38 Importantly, the detection limits for my simple system are as much as 1000-fold
lower than other simple diagnostics such as paper-based microfluidic systems that can detect in
the high nM range.39
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Figure 4.8. Flow distance as a function of logarithm of model target concentration in buffer (solid line), best fit
equation: y = -15.84±0.67 log(x) + 84.4±1.5; and synthetic urine (dashed line), best fit equation: y = -15.78±0.68
log(x) + 77.3±1.5.

Given these detection capabilities, I also tested DNA analogues of a kidney disease miRNA
biomarker, mir-200c-3p,40 and a prostate cancer miRNA biomarker, mir-107,41 in buffer and
synthetic urine (Figure 4.9). As with previous nucleic acid targets, there is a linear correlation
between flow distance and logarithm of nucleic acid concentration with both biomarkers. The
lowest concentration detected for both biomarkers is 10 pg/mL, which is near actual
concentrations of miRNAs in urine (~5 pg/mL).40 I see a small increase in the standard
deviations of slopes and intercepts of these plots compared to the results for the model target
(Figure 4.8), perhaps due to higher GC content in the miRNA analogues (~48% versus 40%).
74

The miRNA analogues are also one base longer than the model target, but this seems less likely
to increase scatter in the data. Importantly, I have shown the ability to detect analogues of
significant miRNA biomarkers in a similar matrix and at levels near those that are clinically
significant, demonstrating strong potential for application of my system in quantifying miRNA
and other nucleic acids in medical applications.

Figure 4.9. Flow distance in receptor-derivatized microchannels as a function of logarithm of concentration of (A)
mir-200c-3p in buffer (solid line), best fit equation: y = -15.9±1.3 log(x) + 75.8±3.0; and synthetic urine (dashed
line), best fit equation: y = -15.99±0.84 log(x) + 78.1±1.9, and (B) mir-107 in buffer (solid line), best fit equation: y
= -16.05±0.78 log(x) + 78.9±1.7; and synthetic urine (dashed line), best fit equation: y = -16.5±1.1 log(x) +
79.5±2.6.
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To move from my present work to miRNA detection in biological samples will require additional
advances. First, RNA experiments require RNase-free conditions, so greater care would need to
be taken in device preparation. Second, miRNAs are present in exosomes in urine, so methods
are needed for making the miRNAs available for hybridization. One method could be to mix the
urine sample with surfactants which will emulsify the lipid bilayer of exosomes, freeing miRNAs
to hybridize with surface attached receptors. With this improvement, it should be possible to
measure miRNA directly from biological fluid such as urine, thus showing huge potential for
point-of-care diagnosis.

4.4 CONCLUSIONS
I have developed a simple, microfabricated flow-based system for sequence-specific nucleic acid
quantitation in biological matrices. I have covalently attached oligonucleotide receptors on
poly(dimethylsiloxane) microchannel surfaces through combined silane and cross-linker
treatments. I found that flow time in addition to flow distance is correlated with target
concentration in my devices. This system can detect specific DNA targets in buffer and synthetic
urine at 10 pg/mL levels. In addition, my approach has a dynamic range of 106 and single-base
mismatch specificity. Finally, DNA analogues of two miRNA biomarkers have been measured
near clinically significant levels, showing great promise for future medical application.

I envision several improvements that can be incorporated in my nucleic acid analysis systems.
Branched channel designs would allow different miRNAs to be quantified simultaneously from
the same sample or for replicate tests to be done on the same biomarker. Designs with a
microchannel extending to the edge of the device would allow direct sample loading without
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pipetting, thus facilitating point-of-care usage. These improvements for nucleic acid analysis in
biological samples should further increase the versatility of my system for rapid and simple
biomarker measurement.

My approach could be extended to other target systems; in addition to miRNA, other RNAs or
DNA biomarkers could be targeted. Furthermore, my methods could be extended to detect small
molecules, ions, or metals through aptamers. For example, surface-attached oligonucleotide
receptors would bind to free aptamer, while aptamer bound to target would not hybridize,
resulting in flow distance differences between the presence or absence of target. The work
described herein demonstrates excellent potential for biological target measurement in a pointof-care setting.
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5. CONCLUSIONS AND FUTURE WORK
5.1 CONCLUSIONS
5.1.1 “Flow valve” microfluidic devices for simple, detectorless, and label-free analyte
quantitation
In Chapter 2, I demonstrated a detectorless microfluidic approach for quantifying target analytes
through simple visual inspection of capillary flow distance in a microchannel. I identified and
characterized three important parameters (solution viscosity, PDMS cover layer thickness and
channel height) that affect the flow distance in these assays for the biotin-streptavidin model
system. In addition, I found a linear relationship between flow distance in biotin-modified
channels and logarithm of streptavidin concentration over a 100,000-fold range of concentrations.
Moreover, I identified and studied a plausible mechanism of channel constriction and how this
leads to concentration-dependent flow distances. Importantly, I have measured streptavidin
concentrations as low as 1 ng/mL using these microsystems, demonstrating low detection limits,
with potential for future improvement.

5.1.2 Evaluation of covalent surface attachment with an antigen-antibody system
In Chapter 3, I demonstrated the detection of a model cancer biomarker, TK1, in flow valve
devices. I developed initial device fabrication and surface modification methods for carrying out
flow assays. Using these conditions, I also verified receptor attachment on channel surfaces
using fluorescence imaging and flow assay results.

In addition, I demonstrated the visual

detection and quantification capability of my system to determine an antigen target, TK1, in
buffer solution. The flow distance in anti-TK1-modified channels correlated linearly with
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logarithm of TK1 concentration over a range of concentrations, with a 1 ng/mL TK1 detection
limit.

5.1.3 Microfluidic devices for label-free and detectorless quantitation of unamplified
nucleic acids by flow distance measurement
In Chapter 4, I developed a simple, microfabricated flow-based system for sequence-specific
nucleic acid quantitation in biological matrices. I covalently attached oligonucleotide receptors
on poly(dimethylsiloxane) microchannel surfaces through combined silane and cross-linker
treatments. I found that flow time in addition to flow distance is correlated with target
concentration in my devices. This system can detect specific DNA targets in buffer and synthetic
urine at 10 pg/mL levels. In addition, my approach has a dynamic range of 106 and single-base
mismatch specificity. Finally, DNA analogues of two miRNA biomarkers were measured near
clinically significant levels, showing great promise for future medical application.

5.2 FUTURE WORK
5.2.1 Flow devices with microfabricated distance scales
Devices for flow assays can have built-in rulers for more accurate flow distance measurement as
seen in Figure 5.1. Photolithography can be used to pattern a millimeter scale ruler on the mold
which would then be imprinted on the device next to the channel during the fabrication process.
This scale would avoid reading errors caused by alignment of a ruler along the microchannel for
flow distance measurement.
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Figure 5.1. Flow valve device with photolithographically patterned millimeter scale flow distance measurement
system.

5.2.2 Device design for direct loading of samples in the flow system
Devices for flow assays can be designed in a way such that biological samples such as urine or
blood (from the prick of a finger) can be loaded directly in the flow system without pipetting.
The design consists of hemispherical channels extending to the edge of the device with an
opening for direct sample entry (see Figure 5.2). This would enhance the potential of the system
for point-of-care usage.

Figure 5.2. A drop of blood from the prick of the finger could enter the flow system directly through the opening on
the side.
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5.2.3 Dual-height channels for flow assays
Chapter 2 describes a plausible mechanism for sensing, where I found that only the first few
millimeters of the channel constrict due to target-receptor interaction. Thus, only the first ~6 mm
need to be derivatized with receptor for target interaction. This finding opens the way to
fabrication of dual height channels (Figure 5.3), for future assays. Dual height channels with an
initial shallow channel height and later taller height should help in containing larger volumes of
fluid without having to fabricate serpentine channels. Master molds for dual height straight
channels can be fabricated by photolithography using two masks (negative and positive) aligned
one after the other on features formed by the first (negative) mask.

Figure 5.3. Dual height channels for flow assays.

5.2.4 Branched channel design for enhancing assay functionality
Branched channel designs could also be used for flow assays (see Figure 5.4). Branches
derivatized with receptors for a particular target could help to carry out replicate tests for
reproducibility studies. Channel branches derivatized with different receptors could be used to
quantify several different targets simultaneously, thus screening for multiple diseases at the same
time.
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Figure 5.4. Branched channel designs for multiplexing. (A) Channels derivatized with receptors for a particular
target. The branch with no receptor could be used for control experiments, where target solutions travels the entire
channel length without stopping. The other branches could be used for target quantitation; replicate tests
simultaneously or different concentrations of target by adding from the right reservoirs. (B) Channels derivatized by
different receptors (receptor 1, receptor 2 and receptor 3) for different target quantitation simultaneously.

One method for derivatizing the channels with different receptors could be by UV
polymerization of solution coated in only one branch of the channel. For example, in Figure 5.4B,
the monomer solution (specific for attachment of receptor 1 upon polymerization) could be
added from reservoir 3 and upon complete filling of that branch, the solution could be removed
by vacuuming from reservoir 3 such that only a small volume of solution remains in the branch,
enough to coat the channel. Then only that branch could be exposed to UV, and the rest of the
branches could be masked to prevent UV light from reaching them. Thus, upon UV exposure, the
solution coated on the wall of the branch with reservoir 3 would be polymerized, and the rest of
the unpolymerized solution from the other branches could be drained by applying vacuum.
Finally, receptor 1 solution when added would only anchor to the branch connected to reservoir 3.
Similarly, the other branches could be exclusively derivatized by specific receptors in specific
channel branches.
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Another method for differential channel derivatization could be with the aid of syringe pumps. In
Figure 5.4B, water could be flowed from reservoir 1 by syringe pump, which would fill all the
branches of the device. Next, a bolus of air could be added from reservoir 3 followed by the
derivatizing fluid by syringe pump with the flow pressure maintained such that the fluid stays
only in that branch for the time period required for derivatization. After the incubation period,
the syringe pump connected to reservoir 3 would be removed, and water from the other branches
would help to wash out unattached material from the derivatized branch. Next, receptor 1
solution could be added, which would attach only to the derivatized branch. Similarly, the other
branches could be derivatized in a stepwise fashion.

5.2.5 Aptamer-based sensing platform
Aptamer-based sensing could be used for targets such as small molecules or ions which are
otherwise difficult to quantify using antigen-antibody interaction. Thus, aptamers bound to
targets could help in indirect quantitation using nucleic acid hybridization as described in
Chapter 4. Examples of targets for aptamer-based sensing are toxic elements such as arsenic and
thrombin, a moiety in the coagulation cascade in blood. Unlike in nucleic acid sensing, the
surface-attached oligonucleotide receptors would be complementary to the aptamer (see Figure
5.5). Thus, only the unbound aptamer would hybridize (Figure 5.5A) and the aptamers bound to
the target would not (Figure 5.5B). High target concentrations would lead to more aptamer-target
bound forms and less free aptamers to hybridize with the receptors, which would lead to longer
flow distances. On the other hand, low target concentrations would have more free aptamers in
solution, thus leading to greater hybridization and, hence, shorter flow distances.
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Figure 5.5. Aptamer-based sensing. (A) Channel constriction from aptamer-receptor hybridization due to free
(unbound) aptamers in solution. (B) Channel open in the absence of hybridization, since all aptamers are bound to
the target.

To conclude, this novel, detectorless platform for analyte quantitation is an excellent
combination of needed analysis capabilities in terms of simplicity and performance. I have
explored protein-protein, including antigen-antibody interactions and nucleic acid hybridization,
and have successfully quantified streptavidin, TK1 and DNA analogues of miRNAs at clinically
relevant levels using my flow devices. Future work with aptamers would expand the range of
potential targets to small molecules and ions. My simple, yet quantitative diagnostic tool has
promise for human health improvement, especially for disease and pathogen detection in
resource-limited settings.

86

